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TDDS : Transdermal drug delivery 
system.
PVA : Poly vinyl alcohol
PVP                     : Poly vinyl pyrrolidone 
EC                                : Ethyl cellulose
HPMC        : Hydroxypropyl methyl 
cellulose
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DM                                  : Diabetes mellitus 
NIDDM                           : Non insulin dependent 
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IDDM                              : Insulin dependent diabetes 
mellitus.
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INTRODUCTION
In the past, the delivery of medications transdermally to a 
patient  has  been  limited  to  administration  by  transcutaneous 
injection or by transdermal migration from a patch placed on the 
outer surface of the patient's skin. It has recently become evident 
that the benefits of i.v can be duplicated using skin as a drug 
delivery route1. It has been necessary for the TDDS to meet two 
requirements.  First,  the  method  must  provide  for  extended 
containment  of  the  drug and any  carrier  while  placed on the 
patient's  skin,  in  a  form  that  does  not  lend  itself  either  to 
contamination of  the medication and carrier  or  to  loss of  the 
medication  and  carrier.  Second,  the  systems  employed  must 
provide for a regulated and predictable rate of transfer of the 
medication (with or without the carrier) from the containment 
device into and through at least some layers of skin to where the 
medication will be dispersed throughout the affected area of the 
body2.
Over the last two decades more than 35 transdermal patch 
products have been approved in US. In 2004 patch sales in the 
US  were  approximately  $3.4  billion.  Prescriptions  for 
transdermal  products  have  been  used  by  ~12  million  people 
worldwide.
Historical Perspecitve
Transdermal delivery of medications was foreshadowed in 
earlier  eras by the use of  certain plasters  and ointments.  The 
mustard  plaster,  applied  as  a  home  remedy  for  severe  chest 
congestion,  may  be  considered  as  an  example.   Powdered 
mustard seed (Brassica nigra) was mixed with warm water, and 
the resulting paste was spread on a strip of flannel, which was 
applied  to  the  patient’s  chest  with  a  cloth  binding  wrapped 
around the body to hold the plaster in place. The moisture and 
body warmth activated an enzyme (myrosin) in the mustard that 
hydrolyzed  a  glycoside  (sinigrin),  causing  the  release  of  the 
pungent  active  ingredient  allyl  isothio-cyanate3.  The  flannel 
served as an impermeable backing and the mustard paste was 
the  reservoir.  In  addition  to  mustard  plasters,  several  other 
plasters  were  recognized in  early  20th century  editions  of  the 
United  States  Pharmacopeia  (USP)  and  National  Formulary 
(NF). At one time, Belladonna Plaster, containing 0.25–0.30% of 
belladonna root alkaloids, was believed to act transdermally as 
an analgesic4.
The  first  transdermal  system  for  systemic  delivery—a 
three-day  patch  that  delivers  scopolamine  to  treat  motion 
sickness—was approved for use in the United States in 1979. A 
decade  later,  nicotine  patches  became  the  first  transdermal 
blockbuster,  raising  the  profile  of  transdermal  delivery  in 
medicine and for the public in general. Between 1979 and 2002, 
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a new patch was approved on average every 2.2 years. In 2003–
2007,  that  rate  has  more  than  tripled  to  a  new  transdermal 
delivery system every 7.5 months. It is estimated that more than 
one billion transdermal patches are currently manufactured each 
year.
           First-generation transdermal  delivery systems have 
continued their  steady increase  in  clinical  use  for  delivery  of 
small,  lipophilic,  low-dose  drugs.  Second-generation  delivery 
systems using chemical enhancers, non-cavitational ultrasound 
and  iontophoresis  have  also  resulted  in  clinical  products;  the 
ability  of  iontophoresis  to  control  delivery  rates  in  real  time 
provides added functionality. Third-generation delivery systems 
target  their  effects  to  skin’s  barrier  layer  of  stratum corneum 
using  microneedles,  thermal  ablation,  microdermabrasion, 
electroporation and cavitational ultrasound5.
TECHNOLOGIES UNDER DEVELOPMENT
       The  technologies  currently  under  development  can  be 
divided into two broad categories. 
Iontophoresis, The ability of an electric current to cause 
charged particles to move. A pair of adjacent electrodes placed 
on the skin set up an electrical potential between the skin and 
the  capillaries  below.  At  the  positive  electrode,  positively 
charged drug molecules are driven away from the skin's surface 
toward  the  capillaries.  Conversely,  negatively  charged  drug 
molecules  would  be  forced  through  the  skin  at  the  negative 
electrode. It has the potential to expand the range of compounds 
available  for  transdermal  delivery  because  the  current  can  be 
literally  switched  on  and  off  and  modified,  iontophoretic 
delivery  enables  rapid  onset  and  offset,  and  drug  delivery  is 
highly controllable and programmable.
Poration  technologies, uses  high-frequency  pulses  of 
energy, in a variety of forms, temporarily to disrupt the stratum 
corneum,  the  layer  of  skin  that  stops  many  drug  molecules 
crossing into the bloodstream. It is important to note that unlike 
iontophoresis,  the energy used in poration technologies is not 
used  to  transport  the  drug  across  the  skin,  but  facilitates  its 
movement. Poration provides a "window" through which drug 
substances can pass much more readily and rapidly than they 
would normally6.
Passive 7
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Reservoir (Androderm, Duragesic)
Active
Iontophoresis
Electroporation
Sonophoresis
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Figure.1:  ADVANCE DEVELOPMENT IN TDDS
PLO:
Pluronic lecithin organogel is a micro emulsion-based gel 
that has been effectively used by physicians and pharmacists to 
deliver  hydrophilic  and  lipophilic  drugs  topically  and 
transdermally  across  the  stratum  corneum.  It  is 
thermodynamically  stable,  viscoelastic,  and biocompatible  gel 
composed of phospholipids (lecithin), organic solvent, and polar 
solvent.  Various  types  of  therapeutic  agents  have  been  easily 
incorporated in PLO to improve their topical drug delivery. PLO 
improves the topical administration of drug mainly because of 
desired  drug  partitioning,  biphasic  drug  solubility,  and  the 
modification of skin barrier system by organogel components. 
Beside  this,  it  shows  low  skin  irritation,  increases  patient 
compliance, reduces side effects, avoids first pass metabolism, 
and  increases  efficiency  of  drug.  In  addition,  PLO  has  been 
shown  in  vivo and  in  vitro to  modulate  the  release  and 
permeation of drugs applied transdermally. Thus, in future, it has 
wide range of applications and opportunities to experiment with 
various drugs in this type of drug delivery system8.One thing 
that seems clear is that the lecithin component of the PLO has 
the ability to act as an amphoteric surfactant and enables many 
drugs to penetrate the dermal layer9.
History:
           PLO is currently generating great interest in US as a 
topical and transdermal drug delivery vehicle. PLO- based drug 
containing  formulations  have  not  yet  been  marketed 
commercially. This may be because the evidence, to date, for its 
efficiency  as,  a  transdermal  vehicle  is  mainly  anecdotal. 
Systemic scientific evidence is limited and little is known about 
its physicochemical properties as a result of the vehicle not has 
been studied in detail in research laboratories.
In the early 1990’s, PLO was developed as a topical and 
transdermal  drug  delivery  vehicle  from the  original  LO’s  by 
Marty  Jones,  an  American  compounding  pharmacist,  and  his 
colleague.  They  prepared  the  original  LO’s  by  adding  small 
amounts of water to an organic solution of lecithin. PLO was 
then produced when they added an aqueous solution of Pluronic 
F127 (a tri-block copolymer, composed of polypropylene oxide, 
sandwiched  between  two  polyethylene  oxide  units)  to  the 
original gel in an attempt to stabilize it. Collaborations between 
local physicians, their patients and the two pharmacists led to 
the incorporation of a number of drugs into PLO and anecdotal 
evidence of its efficacy as a transdermal delivery vehicle. Since 
then, interest in PLO for use in man and animals, especially cats, 
has  increased  dramatically  and  a  range  of  drugs  have  been 
incorporated within PLO. As well as its used as a TDDS, PLO 
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has been investigated and suggested as a vehicle for application 
to the oral cavity 9,10
Areas of application
The site of application can drastically affect the distribution and 
absorption of a drug.
If a systemic effect is desired, the gel should be applied to 
neck, inner thigh, or inner wrist area.
For a local  effect, the gel should be applied directly to the 
joint or painful region.
Components of PLO Gel
Pluronic F-127:
Pluronic  F-27  is  mainly  used  as  an  emulsifying  agent, 
solubilizing  agent,  and  wetting  agent between  15% and  50% 
concentration. It has the unique property of being solid at room 
temperature and liquid at low temperature. Thus, on contacting 
to skin, it forms gel and facilitate proper inunction and adhesion.
Soya lecithin:
Lecithin is a naturally occurring mixture of diglycerides 
of stearic, palmitic, and oleic acids linked to the choline ester of 
phosphoric acid, commonly called phosphatidylcholine. Lecithin 
is thought to be a permeation enhancer as it increases the fluidity 
of  the  epidermis,  stratum  corneum.  It  is  used  as  dispersing, 
emulsifying, and stabilizing agent.
Water (H 2 O):
              Water acts as a stabilizing and structure-forming agent 
in the process of PLO formation. It is also used for solubilizing 
the Pluronic F-127 and polar drugs. 
Isopropyl  palmitate  (IPP)  or  isopropyl  myristate  (IPM):
               Acts as a non-oleaginous emollient with very good 
spreading ability and used for solubilizing the lecithin. It  is  a 
clear,  colorless,  practically  odorless  viscous  liquid  which 
solidifies at low temperature.
Sorbic acid/potassium sorbate:
           Used as preservatives to enhance the shelf life of a  
product.
Therapeutic agents (drugs)
             The drugs which have to be incorporated in PLO should 
satisfy the biological and physicochemical parameters10.
SKIN STRUCTURE AND BARRIER PROPERTIES 
Skin is the most readily accessible organ in the body. Its 
chief functions are protection, temperature regulation, control of 
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water output and sensation. The skin of an average body covers 
a  surface  area  of  approximately  2  sq.  mts.  in  most  adults, 
varying  in  thickness  from  approximately  1.5  to  4  mm  and 
weighing approximately 2 kg. It receives about one third of the 
blood that is circulating through the body11. Skin consists of the 
cellular  outermost  layer,  epidermis  and  relatively  a  cellular 
connective  tissue  matrix  dermis  as  shown  in  figure:2.  Lying 
between these two layers  is  a  sub-  microscopic structure,  the 
basal lamina, which is derived from both the epidermis and the 
dermis and it serves as an anchoring structure.
The epidermis is composed of two parts: the living cells 
of the malphygian layer and the dead cells of the horny layer 
(stratum  corneum).  Epidermis  is  composed  of  4  cell  types; 
keratinocytes,  which  constitutes  approximately  80%  of  the 
epidermis;  melanocytes,  the  source  of  the  melanin  pigment; 
langerhans cells, which are the outmost arm of the immunologic 
system  and  serve  in  host  defense;  merkel  cells,  which  are 
thought  to  function  as  mechanoreceptors  for  the  sensation. 
Keratinocytes  organize  into  strata  within  the  epidermis  form 
inside  to  outside,  stratum germinatum,  stratum spinosum and 
stratum corneum. 
The stratum corneum typically  comprises 10 to 15 cell 
layers  and  is  approximately  10mm  thick  when  dry.  This 
membrance  consisting  of  dead,  anucleate,  keratinized  cells 
embedded  in  the  lipid  matrix,  is  essential  for  controlling  the 
percutaneous  absorption  of  most  drugs  and  chemicals.  The 
barrier  nature  of  the  horny  layer  depends  critically  on  its 
constituents,  75-80%  proteins,  5-15%  lipids  and  5-10% 
unidentified  material  on  a  dry  weight  basis12.  The  protein 
fraction predominantly comprises of keratin filaments which are 
cross– linked by inter molecular disulfide bridges13.  The lipid 
domain is comprised of an organized distribution of intercellular 
lamellae derived from intra cellular granules secreted during the 
epithelial differentiation process14. 
The  dermis  is  3  to  5  mm thick  and is  composed  of  a 
matrix  of  connective  tissue  in  which predominant  bundles  of 
collagen fibrils interlace with elastic tissue and sparse reticular 
fibers12. 
Figure.2: Structure of human skin, with potential routes for 
drug permeation.
Fundamentals of skin permeation. 
 The  sequence  of  transdermal  permeation of  the drug is 
shown in figure:3. The rate of the permeation, dQ/dt across the 
skin tissues can be expressed mathematically by the following 
relationship15. 
dQ/dt=ps (cd-cr)----------------(1)
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Where cd and cr, respectively the concentrations of a skin 
penetrant in the donor compartment (e.g., the drug concentration 
at  the  surface  of  the  stratum  corneum)  and  in  the  receptor 
compartment  (e.g.  Body).  Ps is  the  overall  permeability 
coefficient of the skin tissues to the penetrant as defined by  
Ps=Ks Dss/hs
Where Ks is the partition – coefficient for the interfacial 
partitioning of a penetrant molecule form the solution medium 
or  a  TDDS  on  to  a  stratum  corneum;  Dss  is  the  apparent 
diffusivity  for  the  steady  state  diffusion  of  the  penetrant 
molecule through a thickness of skin tissues; and hs is the overall 
thickness of the skin tissues.
Figure .3: Multilayer skin model showing the sequence of 
transdermal permeation of drug
Analysis of eq. 1 suggests that to achieve a constant rate 
of drug permeation one needs to maintain the drug concentration 
on  the  surface  of  stratum  corneum  (Cd)  consistency  and 
substantially greater than the drug concentration in the body (Cr) 
i.e.,  Cd > Cr; under such a condition eq.1 can be reduced 
   dQ/dt = Ps Cd
The rate of skin permeation dQ/dt becomes a constant, if 
the  magnitude  of  Cd remains  fairly  constant  throughout  the 
course of skin permeation. To maintain Cd at a constant value, it 
is  necessary to make drug release at a rate (Rd) that is  either 
constant or always greater than the rate of skin uptake (Ra) i.e., 
Rd > Ra. By making Rd greater than Ra, the drug concentration 
on the  skin  surface  (Cd)  is  maintained  at  a  level  equal  to  or 
greater  than  the  equilibrium (or  saturations)  solubility  of  the 
drug in the stratum corneum (Cse) i.e., Cd > Cse, and a maximum 
rate of skin permeation (dQ/dt)m , as expressed by equation (2) is 
thus achieved. 
                             (dQ/dt)m = Ps Cse ------------------------(2)
The  other  mechanism of  permeation  involves  diffusion 
through shunts particularly those offered by the relatively widely 
distributed hair follicles and endocrine glands16. Typically 1cm2 
of human skin yields 10 hair follicles, 15 sebaceous glands and 
100  sweat  glands.  However,  the  appendages  provide  a  small 
fractional surface area of approximately 0.1% of the total area. 
Recent studies17 indicate the importance of appendages in 
percutaneous absorption. The appendageal route may be more 
significant  for  ions and large polar  molecules18,  which slowly 
permeates through intact stratum corneum. The major fraction of 
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most diffusants permeates across the bulk of  the intact  horny 
layer.  The  two  potential  micro  pathways  serve  the  stratum 
corneum through the transcellular and intercellular routes. 
The principal pathway taken by the penetrant is decided 
mainly  by  diffusants’s  partition  coefficient.  Most  of  the 
diffusants  permeate  by  both  the  routes19.  The  intercellular 
pathway  is  considered  to  provide  the  principal  route  and  the 
major barrier to the permeation of the most drugs20,21.
POLYMERS FOR TRANSDERMAL DELIVERY
                 The polymer controlls the release of the drug from the 
device. The following criteria should be satisfied for a polymer 
to be used to a trsnsdermal system.
Drug solubility and diffusibility in the polymer.
The  desired  drug  loading  and  its  effect  on  polymer 
integrity.
Compatibility of the polymer with necessary excipients, 
such as solvents and skin permeation enhancers for the 
drug.
Skin compatibility: the effect of moisture occluded under 
the polymer formulation.
Mechanical  properties:  softness,  flexibility, 
conformability,  mechanical integrity.
Ease of fabrication.
Toxicity  and  purity  i.e.,  compliance  with  safety 
requirements of th FDA.
Cost and availability.
Technologies of transdermal delivery system:
Transdermal drug delivery systems are broadly classified 
into the following three types 24 as shown in figure:4.
I. Reservoir systems. In this system, the drug reservoir is 
embedded  between  an  impervious  backing  layer  and  a  rate 
controlling membrane. The drug releases only through the rate-
controlling membrane, which can be microporous or nonporous. 
In the drug reservoir compartment, the drug can be in the form 
of a solution, suspension, or gel or dispersed in a solid polymer 
matrix. On the outer surface of the polymeric membrane a thin 
layer of drug-compatible, hypoallergenic adhesive polymer can 
be applied.
II. Matrix  systems,  Drug-in-adhesive  system.  The 
drug reservoir is formed by dispersing the drug in an adhesive 
polymer and then spreading the medicated polymer adhesive by 
solvent casting or by melting the adhesive onto an impervious 
backing layer.  On top of  the reservoir,  layers  of  unmedicated 
adhesive polymer are applied.
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Matrix-  dispersion  system.  The  drug  is  dispersed 
homogeneously in a hydrophilic or lipophilic polymer matrix. 
This  drug  containing  polymer  disc  is  then  fixed  onto  an 
occlusive base plate in a compartment fabricated from a drug- 
impermeable backing layer. Instead of applying the adhesive on 
the  face  of  the  drug  reservoir,  it  is  spread  along  the 
circumference to form a strip of adhesive rim.
III. Microreservoir systems.  This drug delivery system 
is a combination of reservoir and matrix-dispersion systems. The 
drug  reservoir  is  formed  by  first  suspending  the  drug  in  an 
aqueous solution of water-soluble polymer and then dispersing 
the  solution  homogeneously  in  a  lipophilic  polymer  to  form 
thousands  of  unleachable  microscopic  spheres  of  drug 
reservoirs.  The  thermodynamically  unstable  dispersion  is 
stabilized quickly by immediately cross-linking the polymer  in 
situ.  Polymers  are  used  in  transdermal  delivery  systems  in 
various ways, including as
1. Matrix formers
2. rate-controlling membranes
3. pressure-sensitive adhesives (PSAs)
4. backing layers
5. Release liners.
1. Matrix formers 
The main challenge is in the design of a polymer matrix, 
followed by optimization of the drug loaded matrix not only in 
terms of release properties, but also with respect to its adhesion–
cohesion balance, physicochemical properties, and compatibility 
and stability  with other  components  of  the system as well  as 
with skin25. A monolithic solid-state design often is preferred for 
passive transdermal delivery systems because of manufacturing 
considerations and cosmetic appeal. 
1.a. Cross-linked poly (ethylene glycol) (PEG) networks: 
Biocompatibility  of  PEGs  make  them the  polymers  of 
choice.  Proteins  can  be  delivered  by  PEGs cross-linked  with 
tris(6-isocyanatohexyl)  isocyanurate  by  means  of  a  urethane–
allophanate  bond  to  obtain  polymer  networks  capable  of 
swelling  in  phosphate-buffered  saline  or  ethanol  and forming 
gels. These systems have been shown to release the solutes in a 
biphasic manner.
1.b. Acrylic-acid matrices
Acrylic-acid matrices with plasticizers have been used to 
make  drug–polymer  matrix  films  for  TDDS.  Some  of  the 
polymers that have been reported are Eudragit RL PM, Eudragit 
S-100, Eudragit RS PM, and Eudragit E-100. Eudragit NE-40D 
(a  copolymer  of  ethyl  acrylate  and  methyl  methacrylate),  a 
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nonadhesive  hydrophobic  polymer,  also  has  been  used  as  a 
matrix former. 
1.c. Ethyl cellulose (EC) and polyvinylpyrrolidone (PVP) :
The addition of hydrophilic components such as PVP 26 to 
an insoluble film former such as EC tends to enhance its release-
rate constants. This outcome can be attributed to the leaching of 
the soluble component,  which leads to the formation of pores 
and thus a decrease in the mean diffusion path length of drug 
molecules to release into the dissolution medium. The result is 
higher  dissolution  rates.  Substances  such  as  PVP  act  as 
antinucleating agents that retard the crystallization of a drug. 
1.d. Hydroxypropyl methylcellulose (HPMC):
HPMC, a hydrophilic swellable polymer widely used in 
oral controlled drug delivery, also has been explored as a matrix 
former in the design of patches of propranolol hydrochloride. 
HPMC  has  been  shown  to  yield  clear  films  because  of  the 
adequate  solubility  of  the  drug  in  the  polymer.  Matrices  of 
HPMC without  rate-controlling  membranes  exhibit  a  bursting 
effect. 
1.e. Organogels:
Some  nonionic  surfactants  such  as  sorbitane 
monostearate, lecithin, and Tween tend to associate into reverse 
micelles.  These  surfactants  in  an  organic  solvent,  upon  the 
addition of water,  undergo association reorientation to form a 
gel.  These  organogels  can  be  used  as  a  matrix  for  the 
transdermal delivery of drugs with greater influx.
2. Rate-controlling membranes
Reservoir-type transdermal drug delivery systems contain 
an  inert  membrane  enclosing  an  active  agent  that  diffuses 
through the membrane at a finite, controllable rate. The release 
rate–controlling membrane can be nonporous so that the drug is 
released  by  diffusing  directly  through  the  material,  or  the 
material may contain fluid-filled micropores in which case the 
drug may additionally diffuse through the fluid, thus filling the 
pores. In the case of nonporous membranes, the rate of passage 
of drug molecules depends on the solubility of the drug in the 
membrane and the membrane thickness. 
2.a. EVA:
  EVA  frequently  is  used  to  prepare  rate-controlling 
membranes  in  TDDS  because  it  allows  the  membrane 
permeability to be altered by adjusting the vinyl acetate content 
of  the  polymer.  When  ethylene  is  copolymerized  with  vinyl 
acetate,  the degree of  crystallinity  and the crystalline melting 
point decreases and amorphousness increases.. An increase in Tg 
reflects a decrease in the polymer-chain mobility and hence the 
solute diffusivity27. 
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2.b. Silicone rubber:
 The silicone rubber group of polymers has been used in 
many  controlled-release  devices.  These  polymers  have  an 
outstanding combination of biocompatibility, ease of fabrication, 
and  high  permeability  to  many  important  classes  of  drugs, 
particularly steroids. 
2.c. Polyurethane:
Polyurethane  is  the  general  term  used  for  a  polymer 
derived  from  condensation  of  polyisocyanates  and  polyols 
having  an  intramolecular  urethane  bond  or  carbamate  ester 
bonds (-NHCOO-). Although most polyurethanes presently used 
are  of  the  polyether  type  because  of  their  high  resistance  to 
hydrolysis,  polyester  polyurethanes  recently  have  become  the 
focus of attention because of their biodegradability. 
3. PSAs:
A PSA is  a  material  that  adheres  with  no  more  than 
applied finger pressure, is aggressively and permanently tacky, 
exerts a strong holding force, and should be removable from a 
smooth surface without leaving a residue. The general formula 
for a PSA includes an elastomeric polymer, a tackifying resin, a 
necessary filler, various antioxidants, stabilizers if required, and 
cross-linking agents. When formulating a PSA, a balance of four 
properties must be taken into account: tack, peel adhesion, skin 
adhesion, and cohesive strength.
3.a. Polyisobutylene (PIB):
Isobutylene polymerizes in a regular head-to-tail sequence 
by  low-temperature  cationic  polymerization  to  produce  a 
polymer having no asymmetric carbons. In its unstrained state, 
the polymer is in an amorphous state, and the Tg of the polymer 
is  ~-70  °C.  The  physical  properties  of  the  polymer  change 
gradually with increasing molecular weight. 
3.b. Polyacrylates:
 Acrylic  esters  are  represented  by  the  general  formula 
CH2=CH-COOR.  The  nature  of  the  R  group  determines  the 
properties of each ester and the polymer it forms. Polymers of 
this class are amorphous and are distinguished by their water-
clear color in solution and stability toward aging. As is typical of 
polymer systems, the mechanical properties of acrylic polymers 
improve as the molecular weight increases. 
3.c. Silicones:
Silicone PSAs comprise polymer or gum and a tackifying 
resin. The adhesive is prepared by cross linking the reactants in 
solution  by  a  condensation  reaction.  Unlike  acrylic-,  rubber-, 
and PIB-based adhesives, medical-grade silicone adhesives do 
not  contain  organic  tackifiers,  stabilizers,  antioxidants, 
plasticizers, catalysts, or other potentially toxic extractables.
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3.d. Hot-melt PSAs (HMPSAs):
When  HMPSAs  are  heated,  they  melt  to  a  viscosity 
suitable  for  coating,  but  when they are cooled they generally 
stay  in  a  flowless  state.  HMPSAs  are  advantageous  over 
solvent-based systems because they
• do not require removal and containment of the solvents.
• do not require special precautions to avoid fire.
• are  amenable  to  coating  procedures  other  than  those 
commonly used with solvent-based systems.
• are more easily coated into full  thickness with minimal 
bubbling,  which  often  results  with  solvent-containing 
PSAs.
4. Backing layer
When designing a backing layer, the developer must give 
chemical  resistance  of  the  material  foremost  importance. 
Excipient  compatibility  also  must  be  seriously  considered 
because the prolonged contact between the backing layer and the 
excipients may cause the additives to leach out of the backing 
layer or may lead to diffusion of excipients, drug, or penetration 
enhancer through the layer. The most comfortable backing may 
be the one that exhibits the lowest modulus or high flexibility, 
good  oxygen  transmission,  and  a  high  moisture-vapor 
transmission rate. In a novel modification to the conventional 
design, a patch was fabricated in which the backing itself acted 
as a reservoir for the drug. The upper internal portion of the drug 
reservoir  infiltrated the porous backing and became solidified 
therein after being applied so that the reservoir and the backing 
were unified. This modification enabled the backing itself to act 
as a storage location for the medication-containing reservoir 28. 
5. Release liner
During storage the patch is covered by a protective liner 
that  is  removed  and  discharged  immediately  before  the 
application of the patch to the skin. It is therefore regarded as a 
part of the primary packaging material rather than a part of the 
dosage form delivering the active principle.
 However, because the liner is in intimate contact with the 
delivery  system,  it  should  comply  with  specific  requirements 
regarding the  chemical  inertness  and  permeation to  the  drug, 
penetration enhancer, and water. In case cross-linking is induced 
between the adhesive and the release liner, the force required to 
remove the liner will be unacceptably high 29,30. 
Figure .4: Representative designs of transdermal drug
 delivery systems.
Table.1:  Characteristics of some commercially available 
backing materials:
Table: 2. Examples of marketed TDDS
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ADVANTAGES AND LIMITATIONS OF T.D.D.S
Advantages of TDDS:
• Avoids  vagaries  associated  with  gastro-  intestinal 
absorption  due  to  pH,  enzymatic  activity,  and  food 
interactions.
• It is substitute for oral route.
• Avoids  first  pass  effect  (drug  deactivation  by  digestive 
and liver enzymes)
• It avoids the risks and inconveniences of IV therapy.
• Provides predictable extended duration of activity.
• Extends the activity of drugs with short half lives.
• Multi day therapy with single application.
• Provides capacity to terminate drug effects rapidly.
• Rapid  identification  of  medication  in  emergency  eg., 
unconscious coma patients.
• Minimize inter and intra patient variation.
• Reduces daily dosing, thus improving patient compliance.
Limitations of TDDS:
• Limited time that the patch can remain affixed.
• Variable  intra  and  inter  individual  percutaneous 
absorption efficiency.
• Skin rashes and sensitization.
• Bacterial and enzymatic drug metabolism under the patch.
• Complex technology / high cost.
SELECTION  OF THERAPEUTIC  DRUG CANDIDATES 
FOR TRANSDERMAL DELIVERY:
             The choice of drugs to be delivered is almost a difficult 
one and careful considerations should be given for the selection 
of  suitable  drug  molecule.  The  following  are  some  of  the 
desirable properties of a drug for TDDS 31.
Physico– chemical properties of drug:
• The drug should have a molecular weight of less than 750.
• The drug should possess balanced lipophilic hydrophilic 
characteristics and also have reasonable solubility in both 
lipid and aqueous phases.
• The log P value should be in the range 1-3.
• The melting point should be less than 200°C.
• Saturated aqueous solution of the drug should have pH 
value between 5 and 9.
Biological properties of drug:
• The  biological  half  life  (t  1/2)  should  be  less  than  5-6 
hours.
• The drug should be potent with a daily systemic dose of 
less than 20 mg.
• The drug should not stimulate an immune reaction in the 
skin.
• The drug must not induce a cutaneous irritant or allergic 
response.
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            Finally  in  order  to  obtain the best  candidate  for 
transdermal drug delivery, an attempt should be made to keep 
the melting point as low as possible. Obviously, in some cases, 
there  will  be  a  compromise  between  optimizing  both  the 
partition  and  solubility  parameters  and  incorporation  of  a 
suitable penetration enhancer32, 33,34,35.
PENETRATION ENHANCER:
Penetration enhancers are the substances that facilitate the 
absorption  of  penetrant  through  the  skin  by  temporarily 
diminishing the impermeability of the skin.36, 37, 38.
The properties of ideal penetration enhancers are:
• Pharmacologically inert. 
• Non toxic, non irritating & non allergic 
• Rapid onset of action, predictable and suitable duration of 
action for drug used.
• Readily incorporated into the delivery system. 
• Following removal of the enhancer, the stratum corneum 
should immediately and fully recover its normal barrier 
property. 
• Chemically and physically compatible with the delivery 
system. 
• Commonly used Chemical enhancers are Sulfoxides and 
Similar Compounds 39,40.
Pyrrolidones
Pyrrolidones  have  great  potential  to  be  used  as 
transdermal  permeation  enhancers.  The  most  common  N-
methyl-2-pyrrolidone (NMP) has been used widely to enhance 
the  skin  absorption  of  many  drugs,  (insulin,  ibuprofen,  and 
flurbiprofen). The flux of the anti-inflammatory drug ibuprofen 
increased 16 times. Eg. Azone.
Fatty acids and esters
A large number of fatty acids and their esters have been 
used as permeation enhancers.  A general  trend has been seen 
that  unsaturated  fatty  acids  are  more  effective  in  enhancing 
percutaneous  absorption  of  drugs  than  their  saturated 
counterparts. An increase of 6.5-17.5-fold in the permeation rate 
of  flurbiprofen  was  studied.   They  have  a  greater  enhancing 
effect on lipophilic drugs. Eg. Oleic acid.
Sulfoxides and similar compounds
DMSO, the most  important  compound belonging to the 
category  of  sulfoxides  and  similar  compounds,  enhances  the 
transdermal permeation of a variety of drugs,  like β-blockers, 
ephedrine HCL, and papaverine hydrochloride. It also enhances 
the  release  of  azapropazone  from  its  ointments  .eg. 
Decylmethyl sulfoxide (DCMS).
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Alcohols, glycols, and  glycerides
           Ethanol  is  the most  commonly  used alcohol  as  a 
transdermal penetration enhancer. It increases the permeation of 
ketoprofen  from a  gel-spray  formulation  and  triethanolamine 
salicylate  from a hydrophilic emulsion base.  It  also acts  as  a 
vehicle  for  menthol  in  increasing  the  penetration  of  methyl 
paraben. eg glycerin tricaprylate, Lauryl alcohol.
Cyclodextrin complexes
         Cyclodextrin complexes of a number of drugs have been 
formed,  and  such  a  combination  usually  enhances  the 
permeation  of  drugs.  For  instance,  an  inclusion  complex  of 
piroxicam  with  β-cyclodextrin  increased  the  drug  flux  three 
times across hairless mouse skin.
Amino acid derivatives
Various amino acid derivatives have been investigated for 
their potential in improving percutaneous permeation of drugs. 
N-Dodecyl-l-amino  acid  methyl  ester  and  N-pentyl-  N-acetyl 
prolinate were studied. Application of these two enhancers on 
excised  hairless  mouse  skin  1  hr  prior  to  drug  treatment 
produced  greater  penetration  of  hydrocortisone  from  its 
suspension.
Clofibric acid
            Esters and amides of clofibric acid were studied for their 
permeation-enhancing property using nude mice skin. The best 
enhancement of hydrocortisone-21 acetate and betamethasone-
17-valerate was observed with clofibric acid octyl amide when 
applied 1 hr prior to each steroid. 
Dodecyl-N,N-dimethylamino acetate
DDAA increased the transdermal permeation of a number 
of drugs, like propranolol hydrochloride and timolol maleate. It 
was  found  to  be  as  effective  an  enhancer  as  azone,  but  it 
possesses an advantage over azone: Skin irritation with DDAA 
is reversed in a short time compared to azone41.
EVALUATION  OF TRANSDERMAL DRUG  DELIVERY 
SYSTEMS:
Currently,  tremendous  research  is  going  on  in  the 
evaluation of T.D.D.S. The objective of this research is often to 
find  correlation  between  laboratory  results  (In-vitro)  and  the 
transdermal absorption experienced by living subjects,  so that 
in-vivo experimentation  may  be  curtailed.  There  is  a  definite 
need  for  the  development  and  implementation  of  a  single, 
probably  universal,  dissolution  method  to  assure  patch  –  to– 
patch uniform release.  The aim of  in-vitro experimentation in 
TDDS  is  to  understand  and/  or  predict  the  delivery  and 
penetration of a molecule form the skin surface into the body. 
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TDDS  can  be  described  in  three  principal  stages  for 
understanding in designing of suitable in-vitro experiment42.43
• Delivery of the molecules to the skin Surface 
• Passage of the molecule through the skin 
• Delivery  of  the  molecule  into  the  body  in-  vivo = 
recovery of the molecule in-vitro44.
DIABETES MELLITUS AND ITS TREATMENT 45,46.
             Diabetes mellitus is a chronic metabolic disorder 
characterized  by  a  high  blood  glucose concentration-
hyperglycaemia (fasting plasma glucose > 7.0 mmol/l, or plasma 
glucose > 11.1 mmol/l 2 hours after a meal)-caused by insulin 
deficiency,  often  combined  with  insulin  resistance. 
Hyperglycemia occurs because of uncontrolled hepatic  glucose 
output and reduced uptake of  glucose by skeletal muscle with 
reduced  glycogen  synthesis.  When  the  renal  threshold  for 
glucose reabsorption is  exceeded,  glucose spills  over  into the 
urine  (glycosuria)  and  causes  an  osmotic  diuresis  (polyuria), 
which  in  turn,  results  in  dehydration,  thirst  and  increased 
drinking (polydipsia). 
Insulin  deficiency  causes  increased  breakdown  and 
reduced synthesis of proteins.  Diabetic ketoacidosis is an acute 
emergency.  It  develops  in  the  absence  of  insulin  because  of 
accelerated  breakdown  of  fat  to  acetyl-CoA,  which,  in  the 
absence  of  aerobic  carbohydrate  metabolism,  is  converted  to 
acetoacetate and β-hydroxybutyrate (which cause acidosis) and 
acetone  (a  ketone).  Although  insulin  treatment  has  greatly 
increased the  life  expectancy  of  the  diabetic  patient,  diabetes 
remains the third leading cause of death by disease, the second 
leading cause of blindness, and the second leading cause of renal 
failure.
CONTROL OF BLOOD GLUCOSE
   Glucose is the obligatory source of energy for the brain, 
and physiological control of blood  glucose reflects the need to 
maintain adequate fuel supplies in the form of intermittent food 
intake  and  variable  metabolic  demands.  More  fuel  is  made 
available  by feeding than is  immediately  required and excess 
calories  are  stored  as  glycogen  or  fat.  During  fasting,  these 
energy stores need to be mobilized in a regulated manner. The 
most important regulatory hormone is insulin. 
Increased  blood  sugar  stimulates  insulin  secretion, 
whereas  reduced  blood  sugar  reduces  insulin  secretion. 
Hypoglycemia,  caused by excessive  insulin,  not  only  reduces 
insulin secretion but also elicits secretion of an array of 'counter-
regulatory'  hormones,  including  glucagon,  adrenaline, 
glucocorticoids and  growth  hormone,  all  of  which  increase 
blood glucose. 
CLINICAL MANAGEMENT OF DIABETES
Diet  is  the cornerstone of  the management  of  diabetes, 
regardless  of  the  severity  of  the  symptoms  or  the  type  of 
diabetes. Exercise is also an important component in managing 
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diabetes,  particularly  in  obese  individuals  with  NIDDM who 
may have a component of insulin resistance as a consequence of 
obesity. Treatment regimens that have proved effective include a 
calorie restricted diet in combination with exogenous insulin or 
oral hypoglycemic drugs. However, since diet, exercise, and oral 
hypoglycemic  drugs,  often  because  of  noncompliance  by  the 
patient,  will  not  always  achieve  the  clinical  objectives  of 
controlling  the  symptoms  of  diabetes,  insulin  remains 
universally important in therapeutic management. 
The administration of insulin is required for the treatment 
of Type I (IDDM) and in cases of Type II (NIDDM) that are 
refractory  to  management  with  oral  hypoglycemic  drugs. 
Because the spectrum of patients with diabetes extends from the 
totally  asymptomatic  individual  to  one  with  life-threatening 
ketoacidosis,  therapeutic  management  must  be  highly 
individualized. An important objective is to maintain a Glucose 
level as close to normal as possible without producing frequent 
hypoglycemia or overly restricting the patient’s lifestyle. Many 
diabetics aim to achieve an average blood glucose below 150 
(hemoglobin  A1c  <  7%).  Unstable  or  ketoacidosisprone 
diabetics are difficult to maintain with a single dose of either 
intermediate-  or  long-acting  insulin;  they  usually  require 
multiple  injections  of  combinations  of  short-,  intermediate-, 
and/or long-acting insulin preparations.
For the purpose of rational management, it is appropriate 
to classify diabetes as the following.
• Type 1 diabetes.
• Type 2 diabetes.
Type 1 diabetic  patients  are  usually  young  (children  or 
adolescents) and not obese when they first develop symptoms. 
There is  an inherited predisposition,  with a  10-fold  increased 
incidence in first-degree relative of an index case,  and strong 
associations  with  particular  histocompatibility  antigens  (HLA 
types).  Studies of  identical  twins have shown that  genetically 
predisposed  individuals  must  additionally  be  exposed  to  an 
environmental  factor  such  as  viral  infection  (e.g.  with 
coxsackievirus  or  echovirus).  Viral  infection  may  damage 
pancreatic  B  cells  and  expose  antigens  that  initiate  a  self-
perpetuating autoimmune process. The patient becomes overtly 
diabetic  only  when more  than 90% of  the β  cells  have  been 
destroyed.
Type 2 diabetes is accompanied both by insulin resistance 
(which  precedes  overt  disease)  and  by  impaired  insulin 
secretion, each of which are important in its pathogenesis. Such 
patients  are  often  obese  and usually present  in  adult  life,  the 
incidence  rising  progressively  with  age  as  β-cell  function 
declines.  Treatment  is  initially  dietary,  although  oral 
hypoglycemic drugs usually become necessary, and about one-
third of patients ultimately require insulin. Prospective studies 
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have demonstrated a relentless deterioration in diabetic control 
over the years.
Table:3. DIFFERENCE BETWEEN TYPE 1 AND TYPE 2 DIABETES  47
Characteristics Type 1 Type 2
Other names 
Previously : insulin-dependent diabetes 
mellitus (IDDM) : juvenile-onset diabetes 
mellitus  
Previously  :  non-insulin-dependent 
diabetes mellitus (NIDDM): adult onset 
diabetes mellitus
 Diabetic 
population 
5-10% 90% 
Age of onset 
Usually  <  30  year,  peaks  at  12-14  yr,  rare 
before 6 months, some adults develop type 1 
during the fifth decade 
Usually  >  40  year,  but  increasing 
prevalence among obese children.
Pancreatic 
function 
Usually  none,  although  some  residual  C-
peptide  can  sometimes  be  detected  at 
diagnosis, especially in adults  
Insulin present in low, normal, or high 
amounts 
Pathogenesis 
Associated with certain HLA types; presence 
of  islet  cell  antibodies  suggests  autoimmune 
process
Defect  in  insulin  secretion,  tissue 
resistance to insulin; ↑ hepatic glucose 
output.
Family history Generally not strong 
Strong 
Obesity 
Uncommon  unless  "overinsulinized"  with 
exogenous insulin 
Common (60-90%) 
Ketoacidosis 
history
Often present 
Rare,  except  in  circumstances  of 
unusual stress (eg.infection) 
Clinical 
presentation 
Moderate  to  severe  symptoms  (polyuria, 
polydipsia, fatigue, weight loss, ketoacidosis )
Mild polyuria, fatigue, often diagnosed 
on  routine  physical  or  dental 
examination
Treatment 
Insulin, diet, exercise Diet,  exercise,  insulin,  anti  diabetic 
agents
 
Other specific types of diabetes are : 
• Genetic defects of β-cell function (eg.MODY).
• Diseases of the endocrine pancreas.
• Endocrinopathies 
• Drug or chemical induced.
• Infections.
• Gestational Diabetes Mellitus (GDM) .
SULFONYL UREAS48,49,50 
They lower blood glucose level in normal subjects and in type 
2 diabetics, but not in type 1 diabetics.
MECHANISM OF ACTION:
A. Insulin release from pancreatic β- cells
Sulfonylureas  bind  to  a  140-kDa  high-affinity  sulfonylurea 
receptor  that  is  associated  with  a  β-cell  inward  rectifier  ATP-
sensitive potassium channel. Binding of a sulfonylurea inhibits the 
efflux  of  potassium  ions  through  the  channel  and  results  in 
depolarization.  Depolarization  opens  a  voltage-gated  calcium 
channel and results in calcium influx and the release of preformed 
insulin.
B. Reduction of serum glucagon concentrations
Long-term administration of sulfonylureas to type 2 diabetics 
reduces  serum  glucagon  levels,  which  may  contribute  to  the 
hypoglycemic  effect  of  the  drugs.  The  mechanism  for  this 
suppressive effect of sulfonylureas on glucagon levels is unclear but 
appears to involve indirect inhibition due to enhanced release of both 
insulin and somatostatin, which inhibit A-cell secretion.
C.  Potassium  channel  closure  in  extrapancreatic  tissues
Insulin  secretagogues  bind  to  sulfonylurea  receptors  in 
potassium  channels  in  extrapancreatic  tissues,  but  the  binding 
affinity varies among the drug classes and is much less avid than for 
the  β-cell  receptors.  The  clinical  significance  of  extrapancreatic 
binding  is  not  known.  A  minor  action  reducing  glucagon  and 
increasing  somatostatin  release  has  been  demonstrated.  Hepatic 
degradation of insulin may be slowed.
PHARMACOKINETIC ASPECTS 
Sulfonylureas are well absorbed after oral administration, and 
most  reach  peak  plasma  concentrations  within  2-4  hours.  The 
duration of action varies. All bind strongly to plasma albumin and 
are implicated in interactions with other drugs (e.g. salicylates and 
sulfonamides)  that  compete  for  these  binding  sites.  Most 
sulfonylureas (or their active metabolites) are excreted in the urine, 
so their action is increased in the elderly and in patients with renal 
disease. Most sulfonylureas cross the placenta and enter breast milk.
Sulfonylureas require functional β cells, so they are useful in 
the  early  stages  of  type  2  diabetes.  They  can  be  combined  with 
metformin or with thiazolidinediones. 
DRUG AND POLYMER PROFILE
GLYBURIDE 51,52,53,54
Chemical structure
Chemical Formula: C23H28ClN3O5S
Chemical IUPAC Name:  
5-chloro-N-[2-  [4-(cyclohexylcarbamoylsulfamoyl)  phenyl] 
ethyl] -2-methoxybenzamide.
DESCRIPTION   
GLYBURIDE,  also  known  as  GLIBENCLAMIDE,  is  an 
anti-diabetic drug in a class of medications known as sulfonylureas.
Synonyms 
Apo-Glibenclamide
Glibenclamida [INN-Spanish] 
Glibenclamidum [INN-Latin] 
Glibenclamide
Brand Mixtures 
Glucovance (Metformin + GLYBURIDE)
Average Molecular Weight : 494.0040
State : Solid (odorless, white, 
crystalline compound)
Melting Point  : 169-170oC
Solubility : Solubility of the drug in water 
is  approximately  4  μg/ml  at 
pH 4 and 600 μg/ml at pH 9 
and 3 mg/ml in alcohol.  
LogP : 3.78
DOSAGE
Daily dose : 5 – 15 mg 
Initial :   2.5-5  mg/day,  administered 
with breakfast or with the first main meal of the day. In patients who 
are  more  sensitive  to  hypoglycemic  drugs,  start  at  1.25  mg/day. 
Increase  in  increments  of  no  more  than  2.5  mg/day  at  weekly 
intervals based on the patient's blood glucose response .
Maintenance : 1.25-20  mg/day  given  as 
single or divided doses.
Elderly : Initial: 1.25-2.5 mg/day, increase by 
1.25-2.5 mg/day every 1-3 weeks. 
Transfer From Other Hypoglycemic Therapy Patients Receiving 
Other Oral Antidiabetic Therapy
         Transfer of patients from other oral antidiabetic regimens to 
glyburide should be done conservatively and the initial daily dose 
should be 2.5 to 5 mg.
Patients Receiving Insulin
          Some Type II diabetic patients being treated with insulin may 
respond satisfactorily to glyburide. If the insulin dose is less than 20 
units daily, substitution of glyburide tablets 2.5 to 5 mg as a single 
daily dose may be tried. If the insulin dose is between 20 and 40 
units daily, the patient may be placed directly on glyburide tablets 5 
mg daily as a single dose. If the insulin dose is more than 40 units 
daily, a transition period is required for conversion to glyburide. In 
these  patients,  insulin  dosage is  decreased by 50% and glyburide 
tablets 5 mg daily is started.
How to use: Take this medication by mouth with breakfast or with 
the first main meal.
No of doses per day: 1 -2  (usually once daily; or use as directed by 
the doctor. Some patients, especially those taking higher doses, may 
be directed to take this drug twice a day. The dosage is based on the 
medical condition and response to therapy).
MISSED  DOSE: If  you  miss  a  dose,  take  it  as  soon  as  you 
remember. If it is near the time of the next dose, skip the missed 
dose and resume your usual dosing schedule.
Maximum Dose
Daily doses of more than 20 mg are not recommended.
Reference Range:
Target range Adults
Fasting blood glucose <120 mg/dL
Glycosylated hemoglobin <7%
Drug Category
Antiarrhythmic Agents.
Hypoglycemic Agents.
Sulfonylureas.
Alternative  to  insulin  in  women  for  the  treatment  of  gestational 
diabetes (11-33 weeks gestation).
Indication 
               Indicated as an adjunct to diet to lower the blood glucose in 
patients  with  non-insulin-dependent  diabetes  mellitus  (Type  II) 
whose  hyperglycemia  cannot  be  satisfactorily  controlled  by  diet 
alone.  Glyburide,  is  approximately  150  times  as  potent  as 
tolbutamide on a molar basis and twice as potent as Glipizide.
Pharmacology
Glyburide  (INN),  also  known  as  glibenclamide  (USAN),  a 
second-generation sulfonylurea antidiabetic agent, appears to lower 
the blood glucose acutely by stimulating the release of insulin from 
the pancreas, an effect dependent upon functioning beta cells in the 
pancreatic  islets.  With  chronic  administration  in  Type  II  diabetic 
patients, the blood glucose lowering effect persists despite a gradual 
decline in the insulin secretory response to the drug. Extrapancreatic 
effects may be involved in the mechanism of action of oral sulfonyl-
urea  hypoglycemic  drugs.  The  combination  of  glyburide  and 
metformin may have a  synergistic  effect.  In  addition to  its  blood 
glucose  lowering  actions,  glyburide  produces  a  mild  diuresis  by 
enhancement  of  renal  free  water  clearance.  Glyburide is  twice as 
potent as the related second-generation agent glipizide.
 Mechanism of Action
Sulfonylureas such as glyburide likely bind to ATP-sensitive 
potassium-channel receptors on the pancreatic cell surface, reducing 
potassium conductance and causing depolarization of the membrane. 
Depolarization  stimulates  calcium  ion  influx  through  voltage-
sensitive  calcium  channels,  raising  intracellular  concentrations  of 
calcium ions, which induces the secretion, or exocytosis, of insulin. 
Absorption 
Significant absorption within 1 hour and peak plasma levels 
are reached within 4 hours and low but detectable levels at twenty-
four hours. Mean  serum levels of glyburide,  as reflected by areas 
under the serum concentration-time curve, increase in proportion to 
corresponding increases in dose.
 Toxicity             :   Oral rat LD50: > 20,000 mg/kg. 
                      Oral mouse LD50: 3250 mg/kg.
Protein Binding :  >99% Extensively bound to serum proteins
 
Biotransformation
Primarily hepatic (mainly cytochrome P450 3A4). The major 
metabolite  is  the 4-trans-hydroxy derivative.  A second metabolite, 
the  3-cis-hydroxy  derivative,  also  occurs.  These  metabolites 
contribute no significant hypoglycemic action in humans as they are 
only weakly active.
Half-life elimination : 5-16 hours; may be prolonged with 
renal or hepatic impairment.
Time to peak, serum : Adults: 2-4 hours.
Clearance route : Glyburide is excreted as metabolites 
in the  bile and  urine, approximately 50% by each route. This dual 
excretory  pathway  is  qualitatively  different  from  that  of  other 
sulfonylureas, which are excreted primarily in the urine.
Dosage Forms :  tablets, micronized tablets
Food Interactions 
Avoid alcohol. 
Avoid sugar and sugary food. 
Take 30-60 minutes before breakfast. 
Remarks: Potent but slow acting, marked initial insulinemic action, 
may work when others fail, metabolite excreted in urine as well as in 
bile, single daily dose possible despite short t1/2.
Adverse effects
can cause hypoglycemia (which stimulates appetite and leads 
to weight gain). 
are effective only if β-cells are functional. 
block ATP-sensitive potassium channels in β-cells.
are well tolerated but promote weight gain.
Contraindications
Glyburide are contraindicated in patients with: 
Known hypersensitivity or allergy to the drug. 
Diabetic ketoacidosis, with or without coma. This condition 
should be treated with insulin.
Storage: Store at room temperature away from light and moisture. 
POLYMER PROFILE55
POLYVINYL ALCOHOL
Nonproprietary Names
PhEur  : Poly(vinylis acetas)
USP                 : Polyvinyl alcohol
Synonyms
Airvol;  Alcotex;  Elvanol;  Gelvatol;  Gohsenol;  Lemol; 
Mowiol; Polyvinol;  PVA; vinyl alcohol polymer.
Chemical Name and CAS Registry Number
Ethenol, homopolymer [9002-89-5]
Empirical Formula and Molecular Weight
PVA is a water-soluble synthetic polymer represented by the 
formula  (C2H4O)n.  The  value  of  n  for  commercially  available 
materials  lies  between  500  and  5000,  equivalent  to  a  molecular 
weight range of approximately 20000–200000.
Functional Category
Coating  agent;  lubricant;  stabilizing  agent;  viscosity-
increasing agent.
 Applications in Pharmaceutical Formulation or Technology
PVA  is  used  primarily  in  topical  pharmaceutical  and 
ophthalmic  formulations;  It  is  used  as  a  stabilizing  agent  for 
emulsions  (0.25–3.0%  w/v).  PVA  is  also  used  as  a  viscosity-
increasing  agent  for  viscous  formulations  such  as  ophthalmic 
products. It is used in artificial tears and contact lens solutions for 
lubrication  purposes,  in  sustained-release  formulations  for  oral 
administration, and in transdermal patches. PVA may be made into 
microspheres when mixed with a glutaraldehyde solution.
Description
PVA occurs as an odorless, white to cream-colored granular 
powder.
Pharmacopeial Specifications
TYPICAL PROPERTIES
Melting point:
2288°C for fully hydrolyzed grades;
180–1908°C for partially hydrolyzed grades.
Refractive index : n25D = 1.49–1.53
Solubility : Soluble in water; slightly soluble in ethanol 
(95%); insoluble in organic solvents. Dissolution requires dispersion 
(wetting)  of  the  solid  in  water  at  room temperature  followed  by 
heating the mixture to  about  908°C for  approximately 5 minutes. 
Mixing should be continued while the heated solution is cooled to 
room temperature.
Specific gravity:
1.19–1.31 for solid at 258°C;
1.02 for 10% w/v aqueous solution at 258°C.
Specific heat: 1.67 J/g (0.4 cal/g)
Stability and Storage Conditions
PVA is stable when stored in a tightly sealed container in a 
cool, dry place. Aqueous solutions are stable in corrosion-resistant 
sealed  containers.  Preservatives  may  be  added  to  the  solution  if 
extended storage  is  required.  PVA undergoes  slow degradation  at 
1008°C and rapid degradation at 2008°C; it is stable on exposure to 
light.
Incompatibilities
PVA  undergoes  reactions  typical  of  a  compound  with 
secondary hydroxy groups, such as esterification. It decomposes in 
strong acids, and softens or dissolves in weak acids and alkalis. It is 
incompatible at high concentration with inorganic salts,  especially 
sulfates and phosphates; precipitation of PVA 5% w/v can be caused 
by  phosphates.  Gelling  of  PVA solution  may  occur  if  borax  is 
present.
Safety
PVA is  generally  considered  as  a  nontoxic  material.  It  is 
nonirritant  to  the  skin  and  eyes  at  concentrations  up  to  10%; 
concentrations up to 7% are used in cosmetics. Studies in rats have 
shown that PVA 5% w/v aqueous solution injected subcutaneously 
can cause anemia and infiltrate various organs and tissues 
LD50 (mouse, oral): 14.7 g/kg
LD50 (rat, oral)      : >20 g/kg
Handling Precautions
Observe normal precautions appropriate to the circumstances 
and  quantity  of  material  handled.  Eye  protection  and  gloves  are 
recommended. PVA dust may be an irritant on inhalation. Handle in 
a well-ventilated environment.
POVIDONE
Nonproprietary Names
BP  : Povidone
JP                 : Povidone
PhEur           : Povidonum
USP              : Povidone
Synonyms
E1201;  Kollidon;  Plasdone;  poly[1-(2-oxo-1-pyrrolidinyl) 
ethylene];  polyvidone;  polyvinylpyrrolidone;  PVP;  1-vinyl-2-
pyrrolidinone polymer.
Chemical Name and CAS Registry Number
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8]
Empirical Formula and Molecular Weight
The  USP  28  describes  povidone  as  a  synthetic  polymer 
consisting essentially  of linear  1-vinyl-2-pyrrolidinone groups,  the 
differing degree of polymerization of which results in polymers of 
various  molecular  weights.  It  is  characterized  by  its  viscosity  in 
aqueous solution, relative to that of water, expressed as a K-value, in 
the  range  10–120.  The  K-value  is  calculated  using  Fikentscher’s 
equation.
Functional Category
Disintegrant; dissolution aid; suspending agent; tablet binder.
Applications in Pharmaceutical Formulation or Technology
Although  PVP  is  used  in  a  variety  of  pharmaceutical 
formulations, it is primarily used in solid-dosage forms. In tableting, 
povidone solutions are used as binders in wet granulation processes. 
Povidone  is  also  added  to  powder  blends  in  the  dry  form  and 
granulated  in  situ by  the  addition  of  water,  alcohol,  or 
hydroalcoholic solutions. 
Description
           PVP occurs as a fine, white to creamy-white colored odorless 
or almost odorless, hygroscopic powder. PVP with K-values equal to 
or  lower  than 30 are  manufactured by spray-drying and occur  as 
spheres.  Povidone  K-90  and  higher  K-value  povidones  are 
manufactured by drum drying and occur as plates.
Pharmacopeial Specifications
TYPICAL PROPERTIES
Acidity/alkalinity :  pH = 3.0–7.0 (5% w/v aqueous solution).
Density (bulk) : 0.29–0.39 g/cm3 for Plasdone.
Density (tapped) : 0.39–0.54 g/cm3 for Plasdone.
Density (true) : 1.180 g/cm3
Flowability :    20 g/s for povidone K-15;
                          16 g/s for povidone K-29/32.
Melting point : softens at 1508°C.
Moisture content  : povidone  is  very  hygroscopic,  significant 
amounts of moisture being absorbed at low relative humidities. 
Particle size distribution:
Kollidon 25/30: 90% >50 mm, 50% >100 mm, 5% >200 mm;
Kollidon 90: 90% >200 mm, 95% >250 mm.
Solubility : Freely  soluble  in  acids,  chloroform,  ethanol 
(95%), ketones, methanol, and water; practically insoluble in ether, 
hydrocarbons,  and  mineral  oil.  In  water,  the  concentration  of  a 
solution is limited only by the viscosity  of the resulting solution, 
which is a function of the K-value. 
Viscosity  (dynamic): The  viscosity  of  aqueous  PVP  solutions 
depends on both the concentration and the molecular weight of the 
polymer employed.
Stability and Storage Conditions
PVP darkens  to  some extent  on  heating  at  1508°C,  with  a 
reduction in aqueous solubility. It is stable to a short cycle of heat 
exposure  around  110–1308°C;  steam  sterilization  of  an  aqueous 
solution does not alter its properties. 
 Incompatibilities
PVP is compatible in solution with a wide range of inorganic 
salts,  natural  and  synthetic  resins,  and  other  chemicals.  It  forms 
molecular adducts in solution with sulfathiazole, sodium salicylate, 
salicylic  acid,  phenobarbital,  tannin,  and  other  compounds.  The 
efficacy of some preservatives, e.g. thiomerosal, may be adversely 
affected by the formation of complexes with PVP.
Safety 
PVP has been used in pharmaceutical formulations for many 
years, being first used in the 1940’s as a plasma expander, although 
it  has  now been  superseded  for  this  purpose  by  dextran.  PVP is 
widely used as an excipient, particularly in oral tablets and solutions. 
When  consumed  orally,  PVP  may  be  regarded  as  essentially 
nontoxic since it  is not absorbed from the gastrointestinal tract or 
mucous membranes. 
Handling Precautions
Observe normal precautions appropriate to the circumstances 
and quantity of material handled. Eye protection, gloves, and a dust 
mask are recommended.
HYPROMELLOSE
Nonproprietary Names
BP   : Hypromellose 
JP : Hydroxypropylmethylcellulose   
PhEu            : Hypromellosum
USP             : Hypromellose   
Synonyms :   Benecel  MHPC;  hydroxypropyl  methyl  ether; 
E464;  hydroxypropyl  methylcellulose;  HPMC;  Methocel; 
methylcellulose  propylene  glycol  ether;  methyl 
hydroxypropylcellulose;  Metolose;  pharmacoat;  spectracel  6; 
spectracel 15; tylopur.
Chemical name and CAS registry number
   Cellulose, 2-hydroxypropyl-methyl ether [9004-65-3].
Empirical formula molecular weight
The  PhEur  2002  describes  hypromellose  as  a  partly  O- 
methylated and O-(2- hydroxypropylated) cellulose. It is available in 
several  grades  that  vary  in  viscosity  and  extent  of  substitution. 
Grades may be distinguished by appending a number indicative of 
the apparent viscosity, in mPa s, of a 2 % w/w aqueous solution at 
20°C. Hypromellose defined in the USP 25 specifies the substitution 
type by appending a four- digit number to the nonproprietary name: 
e.g., hypromellose 1828. The first two digits refer to the approximate 
percentage content of the methoxy group (OCH3). The second two 
digits refer to the approximate percentage content of the methoxy 
group  (OCH3).  The  second  two  digits  refer  to  the  approximate 
percentage content of the hydroxy propoxy group (OCH2CH (OH) 
CH3), calculated on a dried basis. Molecular weight is approximately 
10,000 – 1500,000. The JP 2001 includes three separate monographs 
for  hypromellose:  hydroxypropylmethylcellulose  2208,  2906,  and 
2910, respectively.
Functional category
Coating  agent;    film  former;  rate-controlling  polymer  for 
sustained release; stabilizing agent; suspending agent; tablet binder; 
viscosity – increasing agent.
Applications in pharmaceutical formulations or technology
HPMC is  widely  used  in  oral  and  topical  pharmaceuticals, 
particularly  ophthalmic  preparations.  Compared  with 
methylcellulose, HPMC produces solutions of greater clarity, with 
fewer  undispersed   fibres  present,  and  is  therefore  preferred  in 
formulations for ophthalmic use. 
Description
           HPMC is an odorless and tasteless, white or creamy white 
fibrous or granular powder.
Pharmacopeial specifications  
TYPICAL PROPERTIES
Acidity / alkalinity : pH=5.5 – 8.0 for a 1% w/w aqueous 
Solution.
Ash     : 1.5 – 3.0% depending upon the 
grade
Autoignation temperature: 360°C 
Density (tapped)    : 0.557 g/cm3
Density (untapped)    : 1.326 g/cm3
Melting point    : browns at 190 - 200°C ; 
Chars at 225 - 230°C.
Glass transition temperature is 170 - 180°C
Moisture content        :  HPMC  absorbs  moisture  from  the 
atmosphere; the amount of water absorbed depends on the relative 
humidity of the surrounding air.
Solubility: soluble  in  cold  water,  forming  a  viscous  colloidal 
solution;  practically  insoluble  in  chloroform,  ethanol  (95%),  and 
ether,  but  soluble  in  mixtures  of  ethanol  and  dichloromethane, 
mixtures of water and alcohol. Certain grades of hypromellose are 
soluble in aqueous acetone solutions, mixtures of dichloromethane 
and propan-2-ol, and other organic solvents.
Specific gravity         : 1.26
Viscosity (dynamic)          :  wide ranges of viscosity types are 
commercially available. 
Stability and storage conditions:
HPMC powder is a stable material, although, it is hygroscopic 
after drying. Solutions are stable at pH 3-11. Increasing temperature 
reduces the viscosity of solutions. HPMC undergoes a reversible sol-
gel transformation upon heating and cooling, respectively. The gel 
point  is  80-90°C,  depending upon the grade and concentration of 
material.  Aqueous  solutions  are  comparatively  enzyme-resistent, 
providing good viscosity stability during long-term storage. 
Incompatibilities
HPMC  is incompatible with some oxidizing agents. Since it 
is  nonionic,  HPMC will  not  complex with metallic  salts  or  ionic 
organics form insoluble precipitates.
Safety
HPMC  is  widely  used  as  an  excipient  in  oral  and  topical 
pharmaceutical formulations. It is also used extensively in cosmetics 
and food products. HPMC is generally regarded as a nontoxic and 
nonirritant material, although excessive oral consumption may have 
a laxative effect. The WHO has not specified an accepatable daily 
intake of HPMC since the levels consumed were not considered to 
represent a hazard to health.
                                          LD50(mouse, IP): 5 g /kg
                                          LD50(rat, IP)       : 5.2 g /kg
Handling precautions
Observe normal precautions appropriate to the circumstances 
and quantity of material handled. HPMC dust may be irritant to the 
eyes and eye protection is recommended. Excessive dust generation 
should  be  avoided  to  minimize  the  risks  of  explosion.  HPMC is 
combustible.
ETHYLCELLULOSE
Nonproprietary Names
BP : Ethylcellulose
PhEur : Ethylcellulosum
USPNF : Ethylcellulose
Synonyms
Aquacoat ECD; Aqualon; E462; Ethocel; Surelease.
Chemical Name and CAS registry number
Cellulose ethyl ether [9004-57-3].
Functional category
Coating  agent;  suspending  agent;  tablet  binder;  thickening 
agent; viscosity – increasing agent.
Applications in pharmaceutical formulation or technology
EC  is  widely  used  in  oral  and  topical  pharmaceutical 
formulations.  The  main  use  of  EC  in  oral  formulations  is  as  a 
hydrophobic coating agent for tablets and granules. EC coatings are 
used to modify the release to a drug to mask an unpleasant taste, or 
to  improve  the  stability  of  a  formulation;  for  example,  where 
granules are coated with EC to inhibit oxidation. Modified – release 
tablet  formulations  may  also  be  produced  using  EC as  a  matrix 
former.
Description
EC  is  a  tasteless,  free-flowing,  white  or  light  tan-colored 
powder.
Pharmacopeial specifications  
TYPICAL PROPERTIES
Density (bulk) : 0.4 g/cm3
Glass transition temperature : 129-133°C
Moisture content
EC  absorbs  very  little  water  from  humid  air  or  during 
immersion, and that small amount evaporates readily.
Solubility
EC is practically insoluble in glycerin, propylene glycol, and 
water. EC that contains less than 46.5% of ethoxyl groups is freely 
soluble in chloroform, methyl acetate, and tetrahydrofuran, and in 
mixtures  of  aromatic  hydrocarbons  with  ethanol  (95%).  EC  that 
contains  not  less  than  46.5%  of  ethoxyl  acetate,  methanol,  and 
toluene.
Specific gravity : 1.12 - 1.15 g/cm3
Viscosity
The viscosity of EC is measured typically at 25°C using 5% 
w/v EC dissolved in a solvent blend of 80% toluene : 20% ethanol 
(w/w).  Grades  of  EC  with  various  viscosities  are  commercially 
available. They may be used to produce 5% w/v solutions in organic 
solvent  blends  with  viscosities  nominally  ranging  from 7  to  100 
mPas (7-100 cp). Specific EC grades, or blends of different grades, 
may be used to obtain solutions of a desired viscosity. Solutions of 
higher viscosity tend to be composed of longer polymer chains and 
produce strong and durable films.
Stability and storage conditions
EC is a stable, slightly hygroscopic material. It is chemically 
resistant  to  alkalies,  both  dilute  and  concentrated,  and  to  salt 
solutions, although it is more sensitive to acidic materials than are 
cellulose esters.
Incompatibilities
           Incompatible with paraffin wax and microcrystalline wax.
Safety
EC  is  widely  used  in  oral  and  topical  pharmaceutical 
formulations. It is also used in food products. EC is not metabolized 
following  oral  consumption  and  is  therefore  a  noncalorific 
substance. Because EC is not metabolized it is not recommended for 
parenteral products; parenteral use may be harmful to the kidneys.
EC is generally regarded to be a health hazard; the WHO has 
not specified an acceptable daily intake.
LD50 (rabbit, skin): >5 g/kg 
                                  LD50 (rat, oral)      : >5 g/kg
Handling precautions
It is important to prevent fine dust clouds of EC from reaching 
potentially explosive levels in the air. EC is combustible. EC powder 
may be an irritant to the eyes and eye protection should be worn.
POLOXAMER
Nonproprietary Names
BP       :  Poloxamers
PhEur  : Poloxamera
USPNF : Poloxamer
Synonyms
Lutrol;  Monolan;  Pluronic;  poloxalkol;  polyethylene–
propylene  glycol  copolymer;  polyoxyethylene–polyoxypropylene 
copolymer; Supronic; Synperonic.
Chemical Name and CAS Registry Number
a-Hydro-o-hydroxypoly(oxyethylene)poly(oxypropylene) poly 
(oxyethylene) block copolymer [9003-11-6]
Empirical Formula and Molecular Weight
The poloxamer polyols are a series of closely related block 
copolymers of ethylene oxide and propylene oxide conforming to the 
general  formula  HO(C2H4O)a(C3H6O)b(C2H4O)aH.  The  PhEur 
2005 states that a suitable antioxidant may be added.   
Functional Category
Dispersing  agent;  emulsifying  and  coemulsifying  agent; 
solubilizing agent; tablet lubricant; wetting agent.
Applications in Pharmaceutical Formulation or Technology
Poloxamers  are  nonionic  polyoxyethylene–
polyoxypropylene  copolymers  used  primarily  in  pharmaceutical 
formulations  as  emulsifying  or  solubilizing  agents.  The 
polyoxyethylene segment is hydrophilic while the polyoxypropylene 
segment  is  hydrophobic.  All  of  the  poloxamers  are  chemically 
similar  in  composition,  differing  only  in  the  relative  amounts  of 
propylene  and  ethylene  oxides  added  during  manufacture.  Their 
physical and surface-active properties vary over a wide range. 
Description
Poloxamers  generally  occur  as  white,  waxy,  free-flowing 
prilled granules, or as cast solids. They are practically odorless and 
tasteless. At room temperature, poloxamer 124 occurs as a colorless 
liquid.
Pharmacopeial Specifications
TYPICAL PROPERTIES
Acidity/alkalinity : pH = 5.0–7.4 for a 2.5% w/v aqueous 
solution.
Cloud point : >1008°C for  a  1% w/v aqueous solution, 
and a  10% w/v aqueous solution of  poloxamer 
188.
Density : 1.06 g/cm3 at 258°C
Flash point : 2608°C
Flowability : solid poloxamers are free flowing.
HLB value : 0.5–30; 29 for poloxamer 188.
Melting point :
168°C for poloxamer 124; 
52–578°C for poloxamer 188;
498°C for poloxamer 237;
578°C for poloxamer 338;
52–578°C for poloxamer 407.
Moisture content : poloxamers  generally  contain  less  than  0.5% 
w/w water and are hygroscopic only at relative humidity greater than 
80%.
Solubility: solubility varies according to the poloxamer type.
Surface tension :
19.8mN/m  (19.8  dynes/cm)  for  a  0.1%  w/v  aqueous 
poloxamer 188 solution at 258°C;
24.0mN/m  (24.0  dynes/cm)  for  a  0.01%  w/v  aqueous 
poloxamer 188 solution at 258°C; 
26.0mN/m  (26.0  dynes/cm)  for  a  0.001%  w/v  aqueous 
poloxamer solution at 258°C.
Viscosity (dynamic): 1000 mPa s (1000 cP) as a melt at 778°C for 
poloxamer 188.
Stability and Storage Conditions
             Poloxamers are stable materials. Aqueous solutions are 
stable in the presence of  acids,  alkalis,  and metal  ions.  However, 
aqueous solutions support mold growth. The bulk material should be 
stored in a well-closed container in a cool, dry place.
Incompatibilities
           Depending on the relative concentrations, poloxamer 188 is 
incompatible with phenols and parabens.
Safety
            Poloxamers are used in a variety of oral, parenteral, and 
topical  pharmaceutical  formulations and are generally  regarded as 
nontoxic and nonirritant materials. 
Acute animal toxicity data for poloxamer 188 
LD50 (mouse, IV): 1 g/kg,
LD50 (mouse, oral): 15 g/kg, 
LD50 (mouse, SC): 5.5 g/kg, 
LD50 (rat, IV): 7.5 g/kg, 
LD50 (rat, oral): 9.4 g/kg.
Handling Precautions
Observe normal precautions appropriate to the circumstances 
and  quantity  of  material  handled.  Eye  protection  and  gloves  are 
recommended.
REVIEW OF LITERATURE
Veena S Belgamwar10 et.al., Gives a detail insight of pluronic 
lecithin  organogels  (PLOs)  as  a  topical  and  transdermal  drug 
delivery system. PLO is a microemulsion-based gel that  has been 
effectively used by physicians and pharmacists to deliver hydrophilic 
and lipophilic drugs topically and transdermally across the stratum 
corneum.  Various  types  of  therapeutic  agents  have  been  easily 
incorporated in PLO to improve their topical drug delivery. Beside 
this,  it  shows  low  skin  irritation,  increases  patient  compliance, 
reduces  side  effects,  avoids  first  pass  metabolism,  and  increases 
efficiency of drug. In addition, PLO has been shown in vivo and in 
vitro to  modulate  the  release  and  permeation  of  drugs  applied 
transdermally.
Shaila  Lewis55 et.al.,  developed  transdermal  patches  of 
nicotine,  which  are  cost  effective  and  conducive  to  the  Indian 
market.  Two  types  of  patches,  monolayered  and  bilayered,  were 
prepared. The monolayered patch bore a rate- controlling membrane, 
whereas  the  bilayered,  served  as  matrix  type.  The  physical 
characteristics of the patches were evaluated by standard techniques. 
The drug content was found to be uniform in the patches.  In vitro 
release  studies  of  transdermal  patches  showed  a  biphasic  release 
pattern, with diffusion as the dominating mechanism of drug release 
for the matrix type, while the membrane-controlled release nicotine, 
gradually over the 24 h study.
Sanap  G.S56 et.al.,  formulated   transdermal  drug  delivery 
systems of indapamide  by using solvent casting method. Monolithic 
systems were prepared by HPMC and EC polymers by incorporating 
glycerine and dibutyl phthalate as plasticizers, respectively. The  in 
vitro drug release studies indicated that HPMC containing films have 
shown better release than that of EC containing films without any 
permeation  enhancer.  The  various  permeation  parameters  such  as 
flux, permeability coefficient, enhancement ratio and diffusion rate 
constants were determined for all the formulations. The maximum 
flux of 9.08 x 10 2 mg/cm 2 h was observed with HPMC monolithic 
system containing 30% w/w olive oil. A significant improvement of 
flux was observed in the following order: olive oil> linseed oil  > 
sunflower oil > cottonseed oil > coconut oil > castor oil. The in vitro 
release studies revealed that the release was sustained up to 24 h and 
it follows zero-order kinetics.
Jianping  Wang57 et.al.,  prepared Sinomenine  transdermal 
patch by salivation method using PVA and PVP and its properties 
were studied. The releasing rate in vitro of the patch was determined 
by HPLC. Peel test was used to evaluate the adhesion. Acute skin 
irritation test was performed in comparison with formalin (0.8%) by 
using mouse  model.  The Sinomenine  TDDS Patch  was prepared. 
The releasing rate in vitro followed the Higuchi equation (r2  >0.99), 
the releasing amount was beyond 90% in 24h. The peel adhesion to 
steel  (N/25 mm) is  10 or  above.  The skin irritation tests  showed 
negligible erythema and edema. The Sinomenine transdermal patch 
was prepared successfully and it may be beneficial for topical use.
Biswajit  Mukherjee58  et.al.,  Prepared transdermal  matrix 
patches containing the drug,  diclofenac diethylamine with various 
polymeric combinations of PVP and EC and to study the mechanism 
of  release  of  the  drug  from the  patches  and  its  skin  permeation. 
Sorbitan  monolaurate  20  (Span  20),  a  non-ionic  surfactant  was 
added  to  the  concentrations  (0.1% wt/vol),  as  a  skin  permeation 
enhancer.  In  vitro skin  permeation  studies,  with  rat  skin,  using a 
modified Keshary-Chien diffusion cell, were carried out. There was 
about a 29% to 30% enhancement of skin permeation of the drug 
using Span 20 and the formulation with PVP: EC 3:5 shows high 
skin permeation.
Yuveraj  Singh  Tanwar59 et.al.,  formulated  transdermal 
patches of  carvedilol  with a  HPMC-drug reservoir  by the solvent 
evaporation  technique.  In  this  investigation,  the  membranes  of 
Eudragit RL100 and Eudragit RS100 were cast to achieve controlled 
release  of  the  drug.  The  prepared  patches  possessed  satisfactory 
physicochemical  characteristics.  In  vitro  permeation  studies  were 
performed using a K-C diffusion cell across hairless guinea pig skin 
and followed the super case II transport mechanism. The effects of 
non-ionic  surfactants  Tween 80 and Span 80 on drug permeation 
were studied. The non- ionic surfactants in the patches increased the 
permeation rate, Span 80 exhibiting better enhancement relative to 
Tween  80.  Transdermal  patches  consisting  of  the  HPMC-drug 
reservoir with Span 80 as permeation enhancer and rate-controlling 
membranes of  Eudragit  RS100 and Eudragit  RL100 demonstrated 
sustained and controlled release of the drug.
Bagyalakshmi  J60  et.al.,  Developed  ampicillin  sodium 
transdermal  patch  against  Escherichia  coli.  The  efficiency  of 
ampicillin  sodium against  E.  coli  was investigated  in  an  in  vitro 
infection model which simulates human pharmacokinetics. The  E. 
coli stains were exposed to transdermal patch with different kinds of 
polymers  such  as  sodium  alginate,  cellulose  acetate  phthalate, 
HPMC,  chitosan  and  CMC  and  the  drug  releasing  capacity  was 
studied  through  colony-forming  units  (CFU).  The  process  was 
carried out for 24 h at 37°C. It was found out that HPMC was the 
best  polymer  that  gave  less  number  of  CFU,  followed  by  CMC, 
chitosan, CAP and sodium alginate.
Sriniva Mutalik61  et.al.,  developed the membrane controlled 
transdermal systems of glibenclamide and to evaluate with respect to 
various  in vitro  and in vivo  parameters. The membrane moderated 
transdermal systems were prepared using drug containing carbopol 
gel  as  reservoir  and  EC,  Eudragit  RS-100,  Eudragit  RL-100  and 
Ethylene  vinyl  acetate  (EVA)  rate  controlling  membranes.  The 
possible interaction between drug and polymer was studied by IR 
spectroscopy, DSC and HPTLC analysis. The hypoglycemic activity 
of the systems was studied in both normal and diabetic mice. Various 
biochemical  parameters and histopathological  studies were carried 
out. The system with EVA rate controlling membrane was selected 
for  in  vivo experiments.  The  transdermal  system produced  better 
improvement  with  respect  to  hypoglycemic  activity,  glucose 
tolerance test, and exhibited negligible skin irritation. 
Elisabeth  Aparecida62 et.al.,  developed  and  validated  a 
dissolution  test  for  glibenclamide  tablets.  Optimal  conditions  to 
carry out the dissolution test are 500 mL of phosphate buffer at pH 
8.0, paddles at 75 rpm stirring speed, time test set to 60 min and 
using  equipment  with  six  vessels.  The  derivative  UV 
spectrophotometric  method  for  determination  of  glibenclamide 
released  was  developed,  validated  and  compared  with  the  HPLC 
method. The UVDS and HPLC methods showed good linearity at 
the concentrations of 5.0 – 14.0 and 8.0 – 12.0 µg/mL, respectively. 
The least square regression showed excellent correlation coefficient 
r2 =  0.9999  (UVDS)  and  r2 =  0.9988  (HPLC).  Precision  and 
recoveries were 0.42% and 100.25%, respectively.
Mohamed Hassan63 et.al.,  formulate and evaluate polymeric 
matrices  and  membrane  systems  for  their  potential  use  as 
transdermal drug delivery devices. Polymers such as EC, PEG 6000, 
PVP, HPMC, Eudragit RLPM and Eudragit RSPM were employed. 
Plasticizers such as Glycerol and Dibutylphthalate were incorporated 
as a  model  drug.  Ephedrine Hydrochloride was incorporated as a 
model  drug.  Drug  containing  films  were  evaluated  for  thickness, 
uniformity,  weight  variation,  area  variation  and  drug  content 
uniformity, K-C type diffusion cell was used to study  in vitro  drug 
release from matrices and membrane systems. The rate of release of 
ephedrine hydrochloride from Eudragit RLPM: RSPM 60:40 were 
found to be faster than from 40:60, than from 20:80, combinations of 
Eudragit RLPM and Eudragit RSPM respectively. 
Bhalla H.L64 et.al.,  designed suitable matrix type polymeric 
films  containing drug  reservoir,  which  could  form the  basis  of  a 
controlled  release  transdermal  formulation.  Films  were  prepared 
using PVA and PVP along with plasticizers like glycerol and PEG. 
The flux of chlorpheniramine maleate was determined across guinea 
pig,  rabbit  and  human  cadaver  skin  using  a   Valia-Chien  type 
diffusion cell.  The flux of  drug was found to be 0.12+0.08,  0.93 
+0.01.  0.006  ±  0.002  mg/cm2/hr  through  guinea  pig,  rabbit  and 
human cadaver skin respectively. The transdermal permeability was 
found to be 0.48, 3.72, 0.024cm/hr X 10-3 through guinea pig, rabbit 
and human cadaver skin respectively indicating that the drug was 
capable of being transported through the skin.
Kanikkannan N65 et.al., employed solution casting method 
using both glass and mercury substrate was used for the preparation 
of indomethacin patches . K –C type diffusion cell was used for in-  
vitro release  studies.  The  PVA-PVP patches  released  100%  drug 
within the 24 hrs period of study. Eudragit RL100-PVP (8:2) with 
PEG 400 as  plasticizer  yielded smooth  and flexible  patches  with 
good release profiles. The release of drug from many of the Eudragit 
based patches followed the diffusion controlled Higuchi’s model. In 
conclusion, the combinations of PVA-PVP and Eudragit RL100-PVP 
matrices may potentially be developed as a transdermal therapeutic 
system.
Ramesh  Gannu66  et.al., developed  10  nitrendipine 
formulations composed of Eudragit RL 100 and HPMC in the ratios 
of 5:0, 4:1, 3:2, 1:4 in formulations and Eudragit RS 100 and HPMC 
in  the  same  ratios  with  6%v/w  of  carvone  as  penetration 
enhancer,15% v/w  of  PEG as  plasticizer  in  dichloromethane  and 
methanol as solvent system. The prepared TDDS were evaluated for 
in  vitro  release,  ex  vivo  permeation,  moisture  absorption,  and 
moisture  content  and  mechanical  properties.  The  drug  release  in 
24hrs for Eudragit RL100: HPMC and Eudragit RS100: HPMC were 
89.2% and 86.1% respectively. Again formulations Eudragit RL100: 
HPMC  and  Eudragit  RS100:  HPMC  (flux  23.51mcg/hr/cm2 and 
22.98mcg/hr/cm2respectively) showed maximum skin permeation.
Jamakandi  V.G67 et.al., evaluated  the  possibility  of  using 
different polymeric  grades  of HPMC (6cps, 15cps, and K4M) for 
the  development  of  TDDS  of  Nicorandil,  an  antianginal  drug. 
Prepared  matrix  type  patches  were  evaluated  for  their 
physicochemical  characterization  followed  by  in  vitro  evaluation. 
Selected  formulations  were  subjected  for  their  ex  vivo  studies  on 
porcine  ear  skin.  Among  the  different  HPMC  formulations, 
transdermal  patch  with  6cps  and  6%  w/v  DMSO  as  permeation 
enhancer showed maximum release and offered least resistance to 
the movement of drug molecules due to its high hydrophilic nature 
and high water permeability value to water.
Wagh  M.P68 et.al.,  formulated  transdermal  films  with 
hydrophilic polymers (PVA, PVP).  Study was undertaken to report 
film  forming  properties  of  the  polymers  used  and  in  vitro drug 
release from monolithic matrices. The drug loading was performed 
at 0.1% w/w and 0.01% w/w based on the weight of polymers. It 
was found that  PVP,  PVA along with glycerin as  plasticizer  have 
good  film  forming  properties.  Drug  release  followed  zero  order 
kinetics. 
Rajagopal  K69 et.al., prepared  matrix  type  transdermal 
patches  of  nimesulide  by  using  different  polymers  alone  or  in 
combination, (HPMC,EC,MC) dibutyl phthalate as a plasticizer and 
aluminium foil  as  a  backing  membrane.  In  vitro studies  through 
cellophane membrane and excised mice skin in phosphate buffer (pH 
7.4) showed that HPMC: EC (2:2) combination may be a suitable 
polymer combination for development of transdermal drug delivery 
system of nimesulide.
Ubaidulla U70 et.al., studied the improvement of permeability 
of carvedilol from transdermal films, which is made by HPMC as 
polymeric matrix and propylene glycol as plasticizer.  SLS, Tween 
20, DMSO and PEG 400 were used as permeation enhancers. Skin 
permeation  was  studied  by Franz  diffusion cell  using  excised  rat 
abdominal  skin.  The  effect  of  iontophoresis  on  permeation  of 
carvedilol  transdermal  films  were  studied  alone  and  mixed  with 
enhancers.  The  permeation  enhancers  and  iontophoresis 
synergistically enhanced permeability of carvedilol from its films.
Marcela  Ramírez71 et.al., evaluated different  variables  that 
influence  drug  release  from  hydrated  hydrophilic  matrices,  the 
polymer  proportion,  the  drug  dose  and  the  matrix  pH  can  be 
included. These variables have been used to modify the drug release 
rate and to examine its effect on the release mechanism. Hydrated 
matrices were prepared varying the matrix proportion of HPMC, the 
pH and the amount of verapamil hydrochloride loaded. The matrices 
release behavior was examined using 900 mL of an aqueous solution 
of NaCl (0.9%) as dissolution medium. The increase of the HPMC 
matrix proportion reduced the release rate of the drug. The release 
profiles showed zero order kinetics for drug dissolution proportions 
up to 70%. The increase of the matrix pH from 5.0 to 8.0 increased 
the release rate. 
Sara Nicoli72 et.al.,  investigated   in  vitro,  the  kinetics  of 
release  and  permeation  of  caffeine,  chosen  as  model  drug,  from 
bioadhesive  transdermal  films.  Permeation  experiments  were 
performed from films with different drug loadings using rabbit ear 
skin  as  barrier.  In  order  to  characterize  the  release  kinetics  of 
caffeine from the film, a polyethylene membrane, impregnated with 
IPM was employed. The data obtained in the present work suggest 
that  caffeine  release  from  transdermal  bioadhesive  films  was 
controlled either by the permeability characteristics of the skin or by 
the film itself, depending on drug loading. When drug loading is low 
(i.e., caffeine is dissolved in the polymers constituting the film), the 
control  resides  in  the  skin.  When  caffeine  loading  exceeds  its 
solubility in the film, the permeation profile is not linear, but shows 
a sort of burst effect.
Kumar  R73 et.al., gave  an  insight  into  the  considerable 
potential of lecithin organogels (LO’s) in the applications meant for 
topical drug delivery. These systems are currently of interest to the 
pharmaceutical  scientist  because  of  their  structural  and functional 
benefits.  Being  thermodynamically  stable,  LO’s  are  prepared  by 
spontaneous  emulsification  and  therefore  possess  prolonged  shelf 
life. The utility of this novel matrix as a topical vehicle has further 
increased  owing  to  its  very  low  skin  irritancy  potential.  Varied 
aspects  of  LOs  viz  formation,  composition,  phase  behavior,  and 
characterization have been elaborated, including a general discussion 
on the developmental background. 
Saeed Arayne M74  et.al., The in vitro  availability studies of 
glibenclamide in presence of commonly used antacids are present in 
this paper. Glibenclamide is used for the treatment of NIDDM and 
antacids are prescribed to encounter gastric acidity etc. These studies 
were carried out in simulated gastric juice and in buffer of pH 7.4 at 
37  and  48°C.  Aluminum  hydroxide,  aluminum  trisilicate, 
magnesium  oxide,  magnesium  trisilicate,  sodium  bicarbonate, 
calcium  carbonate,  magaldrate  and  simethicone  (2,4-
dimethoxypolysiloxane) antacids were used in these studies. 
Sakellarioul  P75  et.al., studied  the  interactions  and 
partitioning of glycerol in PVA, HPMC and their blends has been 
studied by means of torsional braid analysis (TBA). Glycerol was 
shown  to  be  more  efficient  plasticizer  for  PVA than  HPMC  in 
agreement with solubility parameter prediction. Kelley-Bueche-type 
equations were fitted to the experimental Tg data and initial slopes 
yielded an interaction parameter, Ks, between glycerol and the two 
polymers.  The  compositions  of  the  two  plasticized  phases  were 
calculated from Kelley Bueche expressions fitted to the experimental 
data,  enabling  determination  of  the  glycerol  partition  coefficients 
into  the  two  phases.  In  blends  with  20-60%  PVA,  glycerol 
partitioned  selectively  into  the  PVA-rich  phase  whereas  in  the 
system  with  80%  PVA,  glycerol  partitioned  selectively  into  the 
HPMC-rich inclusions.
Sadashivaiah  R76  et.al., prepared matrix-type  transdermal 
drug delivery systems of haloperidol lactate using different ratios of 
EC: PVP (3:2,  2:3,  4:1,  1:2,  2:1,  and 1:4)  by solvent-evaporation 
technique.  Physicochemical  parameters  were  characterized,  and 
dissolution  studies  of  the  formulated  films  were  performed.  In 
addition, solubility studies at various values of pH were carried out, 
and  partition  coefficient  in  octanol/water  system,  flux,  and 
enhancement ratio were also evaluated.  In vitro permeation studies 
were  done  using  modified  Franz  diffusion  cells  through  human 
cadaver skin utilizing 20% PEG 400 in normal saline.  Higuchi and 
Peppas models were used for optimizing the formulation.
Ting  Li77 et.al.,  evaluated  the  enhancing  effects  of  the 
permeation  enhancers  using  two-chamber  side-by-side  diffusion 
cells  containing  excised  rat  skin.  DSC  was  used  to  evaluate  the 
compatibility between indomethacin and MASCOS 10. Tack, shear 
strength and peel strength were measured to estimate the adhesion of 
the patch because the adhesive is critical for the safety, efficacy and 
quality of the product. The drug content and drug release rate of the 
patch are also essential standards in industrial process, so the work 
was complicated. It was notable that the presence of IPM, oleic acid 
and Tween 80 did not increase indomethacin permeation from the 
transdermal  patches  compared  with  the  transdermal  patches 
containing azone and L-menthol (P > 0.05). 
Lai  Wah  Chan78 et.al., selected  six  grades  of  polyvinyl 
alcohol (PVA),  PVA V (degree of  hydrolysation 99.45%, mol.  wt 
140000—150000) and PVA VI (degree of hydrolysation 98—99%, 
mol.  wt  85000—146000)  for  combination  with PVA I  (degree  of 
hydrolysation 99%, mol. wt 17300) to prepare composite films with 
different  amounts  of  PVA I  and  film thickness.  The  permeability 
coefficients  increased with the amount  of  PVA I in  the PVA V–I 
films.  Conversely,  the  presence  of  PVA I  in  the  PVA VI–I  films 
decreased  the  permeability  of  the  composite  films  to  diclofenac 
sodium. The results indicated that PVA I content in the composite 
films was a critical factor,  affecting the apparent solubility and/or 
swelling properties, and thereby permeability of the composite films.
Sridevi S79 et.al., developed acrylate based transdermal drug 
delivery  system (TDDS) for  glibenclamide  and evaluate  it  for  its 
pharmacodynamic  performance  in  male  wistar  rats.  The  drug 
embedded in a polymeric matrix of polymethyl methacrylate and EC 
was  evaluated  for  its  hypoglycemic  activity  in  normal  and 
streptozotocin  induced  diabetic  rats  in  comparison  with  its  oral 
therapy.  A glucose  tolerance  test  (GTT)  was  conducted  in  oral, 
TDDS  and  control  group.  TDDS  significantly  sustained  the 
hypoglycemic activity for 24hrs in normal rats when compared to 
oral administration where the effect declined after 8 hrs. 
Frankum  James80 et.al., discussed  the  ability  of  PLO  to 
enhance  bioavailability  of  drugs,  clinical  studies  with  topical 
nonsteroidal  anti-inflammatory  drugs,  pharmacokinetics  of 
nonsteroidal anti-inflammatory drugs following topical application, 
side  effects,  and  instructions  for  use.  They  conclude  that  PLO 
provides a topical vehicle base for delivery of analgesic drugs with 
the  advantages  of  significant  reduction  of  severe  side  effects, 
increased  patient  compliance  and  increase  of  potential  analgesic 
effects at the painful site.
Laura  Lee  Sartor81  et.al.,  determined  whether  transdermal 
methimazole was as safe and effective as oral methimazole for the 
control  of  hyperthyroidism  in  cats.  Forty-seven  cats  with  newly 
diagnosed  hyperthyroidism  were  randomized  to  receive  either 
transdermal methimazole in PLO, or oral  methimazole.  Cats were 
evaluated at weeks 0, 2, and 4. Data between the 2 groups and over 
time  were  compared  by  nonparametric  methods.  Although  the 
overall efficacy of transdermal methimazole is not as high as that of 
oral methimazole at 2 weeks of treatment, it is associated with fewer 
GI adverse effects compared to the oral route.
Pandey MS82 et.al., formulated and evaluated the suitability of 
PLO  containing  flurbiprofen  for  topical  application.  Four 
formulations were developed using flurbiprofen,  lecithin,  Pluronic 
F127, isopropyl palmitate, water, sorbic acid and potassium sorbate 
were coded as FL1, FL2, FL3 and FL4. All the formulations carried 
30% w/w of lecithin phase and 70% w/w of Pluronic phase.  The 
formulated  organogels  were  evaluated  for  appearance  and  feel 
psychorheologically, in vitro diffusion study, drug content, viscosity 
and pH. Release of flurbiprofen from all formulations was monitored 
via dialysis membrane-70 and Wistar rat skin as a semi permeable 
membrane into phosphate buffer saline (0.2 M, pH 7.4) using K-C 
diffusion cell. 
Ursula  Krotscheck83  et.al., evaluated  transdermal 
administration of  morphine  and fentanyl  using a  pluronic  lecithin 
organogel  in  dogs.  IV  administration  of  morphine  and  fentanyl 
resulted  in  therapeutic  serum  drug  concentrations.  Following 
transdermal  administration,  however,  median  serum  drug 
concentrations  were  never  above  the  limit  of  quantitation  for 
morphine or fentanyl. These findings indicate that use of a PLO for 
transdermal  administration  of  morphine  or  fentanyl  cannot  be 
justified.
OBJECTIVE
Transdermal  Drug  Delivery  Systems  (TDDS)  have  been 
available on the global market for more than 25 years as a successful 
alternative to systemic drug delivery for selected drug molecules. In 
a  broad  sense,  the  term transdermal  delivery  system includes  all 
topically  administered  drug  formulations  intended  to  deliver  the 
active  ingredient  into  the  general  circulation.  The  advantages  of 
transdermal drug delivery include its ease of use, patient compliance, 
sustained drug delivery, local application and safety. Oral medication 
must pass through the GIT, into the liver where the drugs are broken 
down,  possibly  lowering their  effectiveness.  With  the transdermal 
formulation, drugs enter directly into the bloodstream, reducing the 
risk of gastrointestinal side effects and bypassing breakdown by the 
liver5,84.
Diabetes  is  one  of  the  leading  causes  of  morbidity  and 
mortality  due  to  specific  microangiopathy  and  the  associated 
macroangiopathy.  It  is  the  leading  cause  of  blindness  and  visual 
impairment  in  adults  in  the  western  hemisphere  and  the  risk  of 
cardiovascular disease is two to five times in persons with diabetes, 
as compared to normal adults. The vast majority of diabetic patients 
have Type 2 DM47.
The  prevalence  of  diagnosed  diabetes  has  increased 
dramatically over the past 40 years both in the US and worldwide. In 
1985,  there  were  approximately  30  million  people  with  diabetes 
worldwide; by 1995, this number had escalated to 135 million and 
by 2025, it is projected that there will be an increase in the incidence 
of  diabetes,  affecting  300  million  people.  Most  of  the  expected 
increase  will  be  in  type  2 diabetes,  which accounts  for  >90% of 
cases  of  diabetes,  while  the  incidence  of  Type  1  diabetes  is 
anticipated  to  remain  stable.  By  2025  the  countries  with  largest 
number  of  people  with  diabetes  will  be  in  India  (>57  million, 
prevalence  6%),  China  (>37  million,  prevalence  3.4%),  and  the 
United States (>21 million, prevalence 8.9%)85. 
Glyburide  is  a  sulfonylurea  type  oral  hypoglycemic  drug 
commercially available in the field of drugs in the form of tablets. As 
of 2007, it is one of only two oral anti-diabetics in the World Health 
Organization  Model  List  of  Essential  Medicines (the  other  being 
metformin)86.  As  of  2003,  in  the  United  States,  it  was  the  most 
popular  sulfonyurea87.  Additionally,  recent  research  shows  that 
glyburide improves outcome in animal stroke models by preventing 
brain swelling. A retrospective study showed that in Type 2 diabetic 
patients  already taking glyburide  there  was  improved NIH stroke 
scale scores on discharge compared to diabetic patients not taking 
glyburide. Glyburide formulated therein is a powerful drug, since it 
sometimes  causes,  a  side  effect,  a  significant  and  prolonged 
hypoglycemia, at a small dosage, so the dosage regimen should be 
specially  attentioned79.  Furthermore,  since  numbers  of  diabetes 
mellitus  of  aged  people  are  recently  increasing,  the  dosage  is 
especially important in the administration of the oral hypoglycemic 
drug to aged people. Recently published data suggests that glyburide 
is  associated  with  significantly  higher  annual  mortality  when 
combined with metformin than other insulin-secreting medications88.
In order to reduce the danger of the side effect as mentioned 
above, it is convenient that, if the drug can be made in the form of a 
percutaneously  absorbable  external  skin  treatment  agent,  the 
application amount can be easily adjusted and, in addition, even if 
rapid hypoglycemic action occurs, the agent can be easily removed 
or washed out and therefore, the danger can be avoided.
PLAN OF WORK
The  work  entitled  Formulation,  evaluation  and  in  vitro 
permeation  studies  of  transdermal  glyburide  from  matrix  type 
patches and PLO gels was planned and carried out for a period of 9 
months (May 2009- January 2010) in the following manner.
Phase I :   Literature survey
                                     Design of the study
Phase II       :   Preparation of the standard graphs
Preparation of glyburide transdermal
 patches and PLO gels 
Phase III  :    Evaluation of prepared patches and 
Gels
Compatibility studies using IR spectrophotometer.
Physico- chemical parameters of the patches.
Characterization of PLO.
Phase IV : 
 In vitro drug permeation studies of transdermal 
           formulation  
Stability studies.
Data analysis and project submission. 
                                        
MATERIALS AND EQUIPMENTS USED
Table: 4. Materials Used
 
S. No Material Source
1 Glyburide Gift sample from Micro Labs, Bangalore.
2 Polyvinyl alcohol Sigma Aldrich, Steinheim.
3 Poly vinyl pyrrolidone Sigma Aldrich, Steinhem.
4 Glycerine SD Fine Chemicals, Mumbai.
5 Dimethyl sulfoxide Merck Ltd.
6 Ethylcellulose SD Fine Chemicals, Mumbai.
7 Hydroxypropyl methyl cellulose Himedia Laboratories, Mumbai.
8 Polyethylene glycol 400 Himedia Laboratories, Mumbai.
9 chloroform Qualigens fine chemicals, Mumbai.
10 Methanol SD Fine Chemicals, Mumbai.
11 Mercury SD Fine Chemicals, Mumbai.
12 Calcium chloride Qualigens fine chemicals, Mumbai.
13 Potassium di hydrogen phosphate Qualigens fine chemicals, Mumbai.
14 Sodium hydroxide Qualigens fine chemicals, Mumbai
15 Sodium chloride Qualigens fine chemicals, Mumbai.
16 Pluronic F-127 Sigma Aldrich, Steinheim.
17 Lecithin soya Himedia laboratories Pvt. Ltd, Mumbai.
18 Potassium sorbate Himedia Laboratories Pvt Ltd, Mumbai.
19 Sorbic acid Himedia Laboratories Pvt Ltd, Mumbai.
21 TLC plates Merck Ltd.
22 Cyclohexane Hi-pure fine chem Industries, Chennai.
23 Glacial acetic acid Qualigens fine chemicals, Mumbai.
24 Sodium lauryl sulfate Sigma Chemicals, Steinheim.
25 Tween 80 Indian research products, Mumbai.
26 Cellophane membrane Sartorius Ltd.
Table: 5. Equipments used
S. no Equipment Model / Company
1 Franz Diffusion Cell Fabricated one
2 UV-visible spectrophotometer Jasco V-530
3 FT-IR spectrophotometer Jasco-FT-IR 8201 PC
4 Digital balance Denver instruments
5 Dissolution test apparatus Lab India disso 2000
6 Hot air oven Inlab equipments
7 Magnetic stirrer Remi equipments
8 Circular mould dishes Fabricated one
9 Laboratory stirrer with variable speed control Remi motors
10 Vacuum desiccator -
11 Dial caliper Aerospace electronic digital micrometer
12 Single pan balance Dhona 200 D
METHODOLOGY
Glyburide,  an  important  drug  of  sulfonylurea  class,  is 
currently  available  for  treating  hyperglycemia,  but  has  been 
associated  with  severe  and  sometimes  fatal  hypoglycemia  and 
gastric disturbances like nausea, vomiting, heartburn, anorexia and 
increased appetite after oral therapy. Since these drugs are usually 
intended to be taken for a long period, patient compliance is also 
very important.  In order to reduce the danger of the side effect as 
mentioned above, it is convenient that, if the drug can be made in the 
form of a transdermal formulation.
Preformulation studies:
Before the formulation of a drug substance into a dosage form, 
it  is  essential  that  it  should  be  chemically  and  physically 
characterized.  Preformulation studies give the information needed to 
define the nature of the drug substance and provide a framework for 
the  drug  combination  with  pharmaceutical  excipients  in  the 
fabrication of dosage forms.
In  the  present  work,  pre-  formulation  studies  on  the 
compatibility between drug and polymer were carried out using thin 
layer chromatography and Infra- Red spectroscopy.
THIN LAYER CHROMATOGRAPHY:
A  thin  layer  chromatography  was  carried  out  to  study 
interaction between the drug and polymers. For this the pure drug 
and  its  combinations  with  the  polymers  were  subjected  to 
chromatographic studies.
The following TLC system was used:
Precoated TLC plates : Mfg by S.d fine chemicals
Adsorbant layer : Silica gel G
Layer thickness : 200mµ
Separation technique : Ascending
Size : 10x20cm
Mobile phase : 
Chloroform: cyclohexane: ethanol: glacial acetic acid89
45  : 45       :       5    :      5
Preparation of samples :  a suitable amount of pure drug or 
equivalent  amount  of  the  samples  were  dissolved  in  chloroform: 
methanol (1:1) and were used for spotting.
Amount applied : 10µL
Detection : UV chamber
The Rf values are given in the table:8. and figure:6.
FT/IR Spectral studies
Compatibility  studies  of  the  drug  and  the  polymers  were 
carried  out  using FT/IR  JASCO-410  spectrometer.  1  part  of  the 
sample is mixed thoroughly with 3 parts of dried potassium bromide 
and it was compressed into transparent thin pellets. The pellets were 
scanned  under  IR  region  and  the  spectra  were  recorded  and 
discussed in the later part.
ESTIMATION OF GLYBURIDE:
The following methods are available for the estimation of glyburide
UV spectrophotometric method74.
 LC –MS method Z
HPLC method90
RPHPLC method 91 
Simultaneous estimation of glyburide, gliclazide, glipizide, 
pioglitazone, repaglinide and rosiglitazone by HPLC92.
Simultaneous Estimation of Glyburide and Metformin HCl 
using UV – visible spectroscopy93.
In the present  study, to increase the sensitivity of the assay 
method, UV method was selected for the analysis of glyburide. The 
UV  method  is  simple  and  accurate,  glyburide  exhibits  strong 
absorption at 300 nm respectively (BP 1998).
PREPARATION OF STANDARD GRAPH OF GLYBURIDE:
Standard stock solution:
The  stock  solution  (1mg/ml)  of  glyburide  was  prepared  in 
phosphate buffer solution (pH7.4).
Scanning of glyburide:
           The above prepared standard stock solution was scanned 
under UV region between 200- 400nm and 300nm is found to be the 
absorption  maxima  wavelength  and  same  was  used  for  further 
analysis.
Standard plot:
         From the standard stock solution a series of 
dilutions were made in such a way to obtain 5, 10, 15, 
20, 25 µg/ml concentrations, using phosphate buffer pH 
7.4. The linearity of Glyburide was found to be ranging 
from  5,10,15….50µg/ml.  The  absorbance  were 
measured against  the reagent  blank (phosphate  buffer 
pH  7.4)  using  SHIMADZU  UV  1700 
spectrophotometer  at  300nm  and  were  given  in  the 
table:9.  &  figure:16.  Calibration  graph  was  plotted 
against respective drug concentration versus absorbance 
at 300nm74.      
FORMULATION OF TRANSDERMAL PATCHES
General method of preparation of transdermal patches
In  the  present  study,  matrix  type  transdermal  patches  of 
glyburide  were  prepared  by  moulding  techniques.  A flat  circular 
glass moulds having diameter 4.5cm and height of 1cm with a total 
surface area of 15.91cm2 was fabricated for this purpose.
Preparation of casting solutions94,66
The polymeric solution were prepared by dissolving the PVA 
and PVP combination in water in the ratio 8:2, 6:4, 10:0, 8:0, 0:8, 
0:6. Similarly the polymeric solution of  HPMC and EC combination 
were prepared by dissolving the combination in alcohol: chloroform 
mixture (1:1) in the ratio 2:2, 3:1, 4:0, 3:0, 0:4, 0:3. Glycerine was 
used  as  plasticizer  and  DMSO,  SLS,  Tween  80  as  penetration 
enhancers.  Weighed amount of drug was dispersed in each of the 
polymeric solutions while stirring to ensure the uniform distribution 
of drug. The composition of transdermal patches were listed in the 
table:6. It was placed aside without any disturbances to allow the 
entrapped air to bubble out. 
Table:6.  COMPOSITIONS OF TRANSDERMAL PATCHES OF GLYBURIDE
Materials F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14
Glyburide (mg) 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Glycerin in 
%w/w 20 20 20 20 20 20 20 20 20 20 20 20 20 20
DMSO % w/w 5 5 5 5 5 5 5 5 5 5 5 5 - -
Tween 80 % w/w - - - - - - - - - - - - 5 -
SLS % w/w - - - - - - - - - - - - - 5
PVA in parts 8 6 10 8 - - - - - - - - - -
PVP in parts 2 4 - - 8 6 - - - - - - - -
HPMC in parts - - - - - - 2 3 4 3 - - 2 2
EC in parts - - - - - - 2 1 - - 4 3 2 2
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Table: 7. FORMULATION COMPOSITION OF PLO GELS
Contents % F15 F16 F17 F18 F19
Glyburide (mg) 5 5 5 5 5
Ethanol (ml) 10 10 10 10 10
Soya lecithin in parts 2 3 5 7 3
Sorbic acid (g) 0.2 0.2 0.2 0.2 0.2
Iso propyl palmitate upto (ml) 100 100 100 100 100
Pluronic F-127 in parts 20 20 20 20 30
Potassium sorbate (g) 0.2 0.2 0.2 0.2 0.2
Purified water upto (ml) 100 100 100 100 100
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EVALUATION OF TRANSDERMAL PATCHES
Physical appearance:67
              All the transdermal patches were visually inspected for 
color, clarity, flexibility, and smoothness.
Folding endurance:
             A strip of film (4 × 3 cm) was cut evenly and repeatedly 
folded at the same place till it broke. The number of times the film 
could be folded at the same place without breaking gave the value of 
the folding endurance. 
Thickness of the films:
               The thickness of the drug-loaded polymeric films were 
measured  at  5  different  points  using  a  digital  micrometer.  The 
average and standard deviation of 5 readings were calculated.
Weight uniformity:
The films of different batches were dried at 60oC for 4 hours 
before  testing.  Five  patches  from  each  batch  were  accurately 
weighed in a digital balance. The average weight and the standard 
deviation values were calculated from the individual weights.
Average weight of each patches = total weight of 5 patches/ 5
Standard deviation  = 
Where x = weight of individual patch.
           X = average weight.
           n = number of patches.
Percentage moisture uptake:
             The weighed films were kept in a desiccator at room 
temperature for 24 hours and then exposed to 84% relative 
humidity  using  a  saturated  solution  of  potassium  chloride. 
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Finally,  the  films  were  weighed  and  the  percent  moisture 
uptake was calculated using the formula
Percentage moisture uptake = 
[Final weight - Initial weight/Initial weight] × 100 
Percentage moisture content
         The prepared films were weighed individually and kept in 
a  desiccator  containing  fused  calcium  chloride  at  room 
temperature for 24 hours. The films were again weighed and 
the  percentage  moisture  content  was  calculated  using  the 
formula
Percentage moisture content = 
[Initial weight - Final weight/Final weight] × 100 
Flatness:
            Three longitudinal strips were cut out from each film: 1 from 
the center, 1 from the left side, and 1 from the right side. The length 
of each strip was measured and the variation in length because of 
non-uniformity  in  flatness  was  measured  by  determining  percent 
constriction, with 0% constriction equivalent to 100% flatness. The 
physico-  chemical  parameters  of  the  transdermal  patches  were 
shown in table: 10,11.
Swelling Ratio Measurement 60
Preparation of Disc-Like Specimens
            Discs of the polymers used were prepared by compressing 
500 mg of powder using flat-faced punches 12 mm in diameter to 
yield a hardness of 100 N ± 10. Before swelling tests, the diameter 
and height of each tested disc were measured.
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Swelling Studies
           Swelling studies were performed  by placing the polymeric 
discs  in  petridishes  at  37°C  and  measuring  their  thickness  as  a 
function  of  time during swelling.  The swelling  ratios  of  different 
polymers were given in the table:12. & figure:17. 
In vitro drug release studies
            A Paddle over disc assembly (USP XXIII, Apparatus 2) was 
used for  the assessment of release of drug. The TDDS patch was 
mounted on the disc  and placed at  the bottom of  the  dissolution 
vessel. The dissolution medium was 900 ml phosphate buffer of pH 
7.4. The apparatus was equilibrated to 37 ± 0.5oC and operated at 50 
rpm.  The  samples  (5  ml  aliquots)  were  withdrawn at  appropriate 
time  intervals  up  to  8  hours  and  analyzed  on  a  UV 
spectrophotometer  at  300nm.  The release  profiles  of  formulations 
were shown in table: 14,15. & figure: 18,19.
CHARACTERIZATION OF PLO
Viscosity:82
Viscosities of  the  formulated  organogels  were  determined 
using Brookfield viscometer with Spindle no.7 (Model: RV DV-I ) at 
25°C with the spindle speed of 10 rpm.
pH:
The  pH of  formulated  organogels  was  determined  using  pH 
meter.  The  electrode  was  immersed  in  organogels.  Readings  were 
recorded on pH meter and were shown in the table: 13.
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EVALUATION OF TRANSDERMAL SYSTEMS
Drug content
     Transdermal patches of specified area (3.066 cm2 ) was cut 
into small pieces and PLO formulation of 0.5 g was taken into a 50 
ml  volumetric  flask  and  25  ml  of  phosphate  buffer  pH 7.4  was 
added, gently heated to 45°C for 15 minutes, and kept for 24 hours 
with occasional shaking. Then, the volume was made up to 50 ml 
with phosphate buffer of pH 7.4. Similarly, a blank was carried out 
using a drug-free formulation. The solutions were filtered through 
Whatman filter paper No. 42 and the absorbance was measured at 
300 nm.
In vitro permeation:
The permeation experiments  were performed at  37°C using 
Franz diffusion cells as shown in figure: 5. A cellophane membrane 
was mounted in the diffusion cell  having across sectional  area of 
3.14 cm2. The membrane was tightly secured between the donor and 
receptor  compartments.  The  upper  surface  of  the  membrane  was 
exposed to solution of drug formulation. The receptor compartment 
was filled with 14.5 ml of isotonic phosphate buffer pH 7.4.  The 
donor  compartment  was  sealed to  prevent  evaporation of  the test 
formulation. The franz diffusion cells was connected to thermostatic 
circulating  water  bath  through  stainless  steel  pipes  allowing 
circulation of water through the water jacket surrounding the cell. A 
volume of 1.0 ml  was withdrawn from the receptor  compartment 
from  each  cell  after  each  hour  after  application  of  the  test 
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formulation.  The withdrawn sample was immediately  replaced by 
freshly prepared buffer solution. The samples were analyzed in UV 
spectrometer at 300nm95  and shown in the table: 16-18 & figure:20-
22.
Figure:5. 
STABILITY STUDY96
         The  prepared  patches  and  gels  were  subjected  to  stability 
study by storing the formulations at different storage conditions. The 
formulations were stored for one month at different temperature i.e 
40°C  and  at  room  temperature  (25°C).  The  stability  study  was 
conducted  with  regard  to  moisture  content,  moisture  uptake, 
thickness,  weight  variation,  folding  endurance,  flatness,  in  vitro 
dissolution,  drug  content  for  the  patches  and  pH,  viscosity,  drug 
content  for  the gel  formulation.  The formulations,  which retained 
their  physical  properties,  were  further  subjected  to  in-vitro 
permeation studies and were shown in the table:19-24 & figure:23.
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RESULTS AND DISCUSSION
 Transdermal  drug  delivery  system  of  glyburide  was 
developed using  polymers  like  PVA,  PVP,  HPMC EC employing 
glycerine  as  plasticizer  and  DMSO,  SLS  and  Tween  80  as  the 
permeation  enhancers  for  transdermal  patches  and  PLO  gel  was 
formulated  using  Pluronic  F-127  and  lecithin  phase.  Formulated 
patches  were  subjected  to  physico-  chemical  evaluations  such  as 
physical  appearance,  weight  variation,  thickness,  %  moisture 
content, % moisture uptake, flatness, and drug content, and the PLO 
formulation were tested for physical appearance, pH, and viscosity. 
The in vitro drug release studies across cellophane membrane were 
conducted  and  the  best  formulations  were  subjected  to  stability 
studies.
COMPATIBILITY STUDIES:
The  compatibility  studies  confirmed  that  the  absence  of 
chemical  interaction  between  drug  and  the  polymers  used.  The 
physico- chemical parameters were evaluated.
Thin layer chromatography:
TLC for the pure drug and in combination with the polymers 
were performed as shown in figure:6. The Rf values were reported in 
the  table:8.  The  Rf  values  indicate  the  absence  of  chemical 
interaction between the drug and the polymers used.
FT/IR Spectral studies
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Compatibility  studies  of  the  drug  and  the  polymers  were 
carried  using  JASCO/FT/IR  spectrometer  and  the  spectras  were 
given in the figure:7-15. The IR spectra obtained from the mixture of 
polymers and drug was matching with the spectra of the pure drug. 
There  was  no  appearance  or  disappearance  of  any  characteristic 
peaks, which confirmed the absence of chemical interaction between 
the drug and the polymer used.
THIN LAYER CHROMATOGRAM DETAILS:
Table:8. Rf values of drug and the polymers
S. no SAMPLE Rf VALUE
1 Drug 0.42
2 Drug + PVA +PVP 0.41
3 Drug + PVA 0.41
4 Drug +PVP 0.42
5 Drug + HPMC +EC 0.41
6 Drug + HPMC 0.42
7 Drug + EC 0.42
8 Drug + Pluronic F-127 0.42
Figure:6.  TLC of Glyburide along with polymers
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Figure:7. IR SPECTRA OF GLYBURIDE
Figure:8. IR spectra of POLYVINYL ALCOHOL
Figure:9. IR spectra of POLYVINYL PYRROLIDONE
Figure:10. IR spectra of HYDROXYPROPYL METHYL CELLULOSE
Figure:11. IR spectra of ETHYL CELLULOSE
Figure:12. IR spectra of PLURONIC F-127
Figure:13. IR spectra of PVA+PVP+GLYBURIDE
Figure:14. IR spectra of HPMC+ EC + GLYBURIDE
Figure:15. IR spectra of PLURONIC F-127 + GLYBURIDE
Fig:15. IR spectra of PLURONIC F-127 + GLYBURIDE
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Table:9. Calibration graph of glyburide
Sl. No. Concentration mcg/ml Absorbance @ 300nm
1 5 0.2636 ± 0.02
2 10 0.5231 ± 0.01
3 15 0.7820 ± 0.04
4 20 1.0250 ± 0.02
5 25 1.2811 ± 0.05
Figure:16. Calibration graph of glyburide
Calibration curve  : linear
Expression           : Abs = A + B* Conc
Factor                  : A = 0.0139
                               B = 0.0507
Coefficient           : 0.999935
PHYSICO- CHEMICAL PARAMETERS
Transdermal patches
The results of the physico- chemical  characterization of the 
fourteen  patches  were  shown  in  the  table:  10,  11.  The  weights 
obtained by the formulated transdermal patches were between 0.28g 
and 0.57g.
For all the formulation the thickness varied between 0.11 to 
0.16mm.  The  low values  for  standard  deviation  indicate  physical 
uniformity of the patches.
The moisture uptake studies revealed that all the formulated 
transdermal  patches  were  having  the  low  moisture  uptake  and 
moisture content when compared with formulations F5 and F6. The 
reason for increase in moisture uptake and content for F5 and F6 
may be attributed to the hygroscopic nature of the polymer,  where 
F11,  F12  transdermal  patches  has  the  least  moisture  content  and 
uptake due to the hydrophobic nature of the polymer. 
Percentage  of  swelling  index  for  all  the  polymers  used  in 
transdermal  patches  were  between  0.5  -  13.9%.  The  order  of 
increasing swelling  index of  the polymers  are  as  follows,  PVP > 
HPMC  >  PVA >  EC.  The  results  are  given  in  the  table:12  & 
figure:17.   
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Table:10. Physico-chemical parameters of the formulated transdermal patches of glyburide- F1 to F7
Parameters F1 F2 F3 F4 F5 F6 F7
Physical 
appearance
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
Weight 
variation(g) 0.55 +0.01 0.42 + 0.01 0.57 + 0.1 0.55 + 0.08 0.19 + 0.06 0.18 + 0.01 0.35 + 0.04
Thickness
(mm) 0.14+ 0.008 0.16+ 0.001 0.13+ 0.004 0.12+ 0.012 0.14+ 0.007 0.16+ 0.009 0.16+ 0.008
%moisture 
uptake 20.7 26.7 20.1 30.5 72.5 54.3 25.3
%moisture 
content 2.9 3.0 2.2 1.4 3.6 3.6 3.3
Folding 
endurance 350 361 348 340 375 360 245
%Drug 
content 101.1 100.7 99.7 100.1 99.2 100.3 99.8
%Flatness 99.9 99.9 100 100 99.8 99.9 99.9
Table: 11. Physico-chemical parameters of the formulated transdermal patches of glyburide- F8 to F14
Parameters F8 F9 F10 F11 F12 F13 F14
Physical 
appearance
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth 
and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
flexible, 
smooth and 
transparent
Weight 
variation(g) 0.34 + 0.06 0.31 + 0.05 0.29 + 0.01
0.42 + 
0.03 0.40 + 0.06 0.36 + 0.02 0.35 + 0.01
Thickness
(mm) 0.13+ 0.006
0.13+ 
0.004 0.13+ 0.011
0.11 + 
0.004 0.11 +0.001 0.16 + 0.001 0.16 + 0.003
% moisture 
uptake 25.6 26.9 27.3 1.2 1.0 24.9 25.0
% moisture 
content 3.1 2.3 1.8 0.46 0.5 3.0 3.2
Folding 
endurance 256 278 265 155 175 245 245
% Drug 
content 100.5 99.8 98.5 100 99.3 100.0 99.8
%Flatness 100 99.5 99.8 99.8 100 100 100
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  Folding  endurance  test  results  indicated  that  the  patches 
would not break and would maintain their integrity with general skin 
folding when applied. Folding endurance was in the range of 155 to 
375, transdermal  patch F11 representing the least value, due to the 
brittle nature of EC and F5 has the maximum folding endurance due 
to the hydrophilic nature.
Good  uniformity  of  drug  content  among  the  batches  were 
observed with all formulations and ranged from 98.5% to 101.1%. 
The results indicate that the process employed to prepare patches in 
this  study  was  capable  of  producing  patches  with  uniform  drug 
content and minimal patch variability. 
The flatness study showed that all  the formulations had the 
same  strip  length  before  and  after  their  cuts,  indicating  ~100% 
flatness. Thus, no amount of constriction was observed; all patches 
had  a  smooth,  flat  surface;  and  that  smooth  surface  could  be 
maintained when the patch was applied to the skin.
From  the  In  vitro dissolution  and  diffusion  studies  it  was 
found  that  F7  formulation  showed  better  release  pattern  when 
compared with the other formulations. This is due to the addition of 
hydrophilic  component  HPMC  to  an  insoluble  film  former  EC, 
where  HPMC tends  to  enhance  the  release,  and  EC sustains  the 
release rate. Among the permeation enhancers used formulation F7 
containing DMSO as permeation enhancer showed a better release 
pattern when compared with the formulation  F13 and F14 which 
contains Tween 80 and SLS respectively. The results were given in 
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the table:14-17 & figure:18-21. An increase in the proportion of PVP 
polymer caused an increase in the amount of drug diffused causing a 
initial bursting release, as they are permeable to aqueous medium but 
the  films  were  sticky  and  difficult  to  handle  when  it  absorbs 
moisture.  F11,  F12  showed  the  least  release  due  to  minimum 
swelling  and  showed  higher  resistance  to  the  permeation  of 
lipophilic drug due to its hydrophobic nature.
Pluronic lecithin organogel:
Increase  in  lecithin  content  increases  the  viscosity  of  the 
formulation  and  this  might  be  due  to  the  formation  of  complex 
networks. Formulation F18 with 7% lecithin has maximum viscosity. 
Further  increase  in  concentration  of  lecithin  decreased  the 
cumulative percent drug release which might be due to the extensive 
formation  of  network  like  structure  with  very  high  velocity.  The 
formulation F16, containing 20% pluronic and 3% lecithin showed 
higher cumulative percent drug release as shown in the table:18 & 
figure:22. The pH of all the formulations was around the skin pH 
(5.81 to 6.65) and was smooth and free from grittiness. The drug 
content of gels ranged from 98.6 -100.8% and were reported in the 
table:13.
Table:12. % SWELLING INDEX OF POLYMERS USED IN 
TRANSDERMAL PATCHES
POLYMERS % S.I
PVA 5.6
PVP 13.9
HPMC 12.2
EC 0.5
PVA:PVP
8  : 2 5.8
PVA:PVP
6  : 4 6.8
HPMC:EC
2   : 2 3.9
HPMC:EC
3  : 1 7.6
Table:13. EVALUATION STUDIES OF PLO GELS
Evaluations F15 F16 F17 F18 F19 F20
pH 5.81 6.52 6.11 6.65 5.99 6.43
Viscosity (poise) 2932 3204 3360 3436 2804 2752
% Drug  content 98.63 100.79 100.22 100.87 100.11 99.16
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Figure:17. % SWELLING INDEX OF POLYMERS USED IN TRANSDERMAL PATCHES
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Table:14. In vitro dissolution studies from transdermal patches F1- F7
Formulation 
code
Cumulative 
percentage 
release of 
drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h
F1 5.11± 0.09 11.62± 0.08 22.36± 0.01 26.42± 0.05 37.61± 0.06 40.29± 0.05 42.32± 0.04 46.49± 0.05
F2 10.36± 0.01 12.27± 0.01 16.32± 0.03 21.27± 0.07 39.36± 0.04 42.66± 0.04 49.39± 0.01 51.34± 0.06
F3 3.61± 0.02 6.23± 0.03 13.84± 0.06 27.98± 0.03 36.65± 0.01 39.53± 0.01 47.18± 0.06 49.97± 0.06
F4 1.18± 0.04 2.64± 0.03 4.89± 0.08 10.17± 0.04 21.63± 0.09 28.54± 0.06 31.98± 0.01 34.21± 0.02
F5 22.23± 0.05 23.59± 0.05 26.87± 0.01 29.68± 0.05 30.42± 0.03 30.88± 0.02 31.21± 0.02 32.36± 0.01
F6 18.51± 0.08 20.27± 0.04 21.68± 0.1 24.96± 0.01 27.84± 0.12 29.62± 0.01 30.34± 0.03 34.9± 0.01
F7 5.01± 0.04 10.81± 0.03 15.29± 0.09 22.38± 0.05 29.77± 0.03 36.54± 0.05 41.61± 0.04 48.74± 0.04
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Figure:18. In vitro dissolution profile of formulated transdermal patches F1- F7
Table:15. In vitro dissolution studies from transdermal patches F8- F14
Formulation 
code 
Cumulativ
e 
percentage 
release of 
drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h
F8 3.00± 0.08 5.81± 0.04 9.62± 0.01 21.44± 0.03 22.93± 0.01 29.77± 0.12 49.88± 0.03 56.61± 0.05
F9 0.9± 0.04 1.00± 0.04 3.00± 0.08 6.00± 0.01 17.64± 0.08 26.98± 0.04 30.66± 0.04 31.52± 0.08
F10 2.97± 0.01 4.44± 0.05 5.32± 0.04 7.39± 0.08 13.44± 0.03 29.68± 0.05 32.47± 0.09 33.11± 0.04
F11 0.81± 0.03 0.92± 0.06 1.99± 0.08 3.82± 0.07 3.88± 0.06 07.79± 0.06 9.38± 0.01 11.45± 0.03
F12 1.04± 0.01 1.29± 0.07 1.68± 0.01 2.34± 0.04 5.86± 0.02 06.33± 0.05 6.59± 0.03 11.63± 0.02
F13 4.99± 0.02 11.43± 0.08 13.12± 0.02 20.68± 0.03 25.14± 0.02 30.44± 0.07 40.73± 0.04 45.66± 0.03
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F14 3.66± 0.03 8.74± 0.09 10.67± 0.05 15.96± 0.05 21.36± 0.01 27.47± 0.02 37.81± 0.05 43.45± 0.04
Figure:19. In vitro dissolution profile of formulated transdermal patches F8- F14
Table:16.  Cumulative percentage permeation studies from transdermal patches F1 – F7
Formulation 
code
Cumulative 
percentage 
release of 
drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h
F1 18.34± 0.02 21.89± 0.05 24.69± 0.06 25.63± 0.01 26.29± 0.05 30.32± 0.05 56.18± 0.01 64.99± 0.01
F2 19.23± 0.07 27.21± 0.06 31.35± 0.09 35.01± 0.03 41.86± 0.06 47.74± 0.09 57.28± 0.02 65.54± 0.04
F3 2.68± 0.06 2.95± 0.01 5.42± 0.06 8.37± 0.04 10.04± 0.01 24.17± 0.04 32.64± 0.04 42.04± 0.05
F4 3.13± 0.02 4.72± 0.01 5.44± 0.04 8.12± 0.04 16.14± 0.1 31.00± 0.03 38.91± 0.04 63.24± 0.06
F5 43.08± 0.01 43.68± 0.04 44.36± 0.02 44.96± 0.01 45.58± 0.04 46.18± 0.04 46.81± 0.09 47.40± 0.07
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F6 40.30± 0.04 41.50± 0.05 42.37± 0.01 43.86± 0.03 45.17± 0.05 45.79± 0.06 46.39± 0.05 46.98± 0.08
F7 10.06± 0.03 20.45± 0.06 30.88± 0.02 37.54± 0.06 47.87± 0.07 56.99± 0.02 70.53± 0.04 74.45± 0.01
Figure:20. In vitro permeation profile of formulated transdermal patches F1- F7
Table:17.  Cumulative percentage permeation studies from transdermal patches F8 – F14
Formulation 
code
Cumulativ
e 
percentage 
release of 
drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h
F8 8.06± 0.01 8.48± 0.03 18.77± 0.08 27.2± 0.03 34.16± 0.05 43.19± 0.01 48.49± 0.06 57.65± 0.05
F9 12.86± 0.04 24.11± 0.04 34.78± 0.04 42.15± 0.05 53.32± 0.05 57.38± 0.02 63.83± 0.01 68.80± 0.03
F10 9.49± 0.09 17.56± 0.03 26.46± 0.05 37.23± 0.06 51.05± 0.06 63.64± 0.03 65.13± 0.03 66.65± 0.04
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F11 0.33± 0.04 0.6± 0.01 1.83± 0.05 2.54± 0.07 6.51± 0.02 7.06±  0.06 7.18± 0.04 7.74± 0.01
F12 0.39± 0.05 1.28± 0.03 1.38± 0.06 1.41± 0.01 1.57± 0.03 2.01±  0.05 4.08± 0.05 6.85± 0.02
F13 10.30± 0.01 16.70± 0.04 24.58± 0.03 36.08± 0.03 43.82± 0.01 49.90± 0.03 58.39± 0.07 72.42± 0.03
F14 9.19± 0.01 13.51± 0.02 28.02± 0.05 35.81± 0.03 41.86± 0.02 50.72± 0.01 57.51± 0.03 64.24± 0.03
Figure:21. In vitro permeation profile of formulated transderrmal patches F8- F14
Table:18.  Cumulative percentage permeation studies from PLO gels  F15 – F20
Formulation
 code
Cumulative 
percentage 
release of 
drug at
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h
F15 10.36± 0.03 12.49± 0.03 14.31± 0.04 19.26± 0.04 21.75± 0.03 30.55±  0.1 44.99± 0.1 50.23± 0.05
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F16 24.75± 0.05 28.80± 0.05 33.67± 0.07 37.21± 0.03 46.3± 0.01 55.19± 0.09 62.62± 0.04 79.37± 0.06
F17 5.39± 0.06 10.23± 0.05 10.44± 0.03 10.85± 0.05 11.49± 0.09 18.7±  0.07 20.46± 0.01 25.69± 0.04
F18 2.47± 0.05 2.96± 0.04 4.24± 0.01 7.71± 0.06 10.39± 0.08 15.75± 0.03 22.09± 0.03 25.63± 0.08
F19 9.07± 0.03 10.21± 0.09 22.99± 0.02 29.09± 0.01 37.73± 0.04 45.39± 0.06 50.02± 0.06 67.27± 0.07
F20 5.49± 0.01 5.68± 0.06 11.72± 0.03 23.04± 0.03 35.85± 0.07 47.81± 0.01 50.06± 0.04 62.58± 0.03
Figure: 22. In vitro permeation profile of PLO gels F15- F20
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Stability studies:
The  selected  formulations  were  stored  at  room temperature 
(25°C) and at 40°C for a period of 30 days and were assessed for any 
changes in their physico- chemical properties and in vitro diffusion 
through cellophane membrane. There was no appreciable difference 
in  the  diffusion  pattern  and  physico-  chemical  properties  of  the 
formulations after 30 days and were shown in the table: 19-24 & 
figure :23.
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Table:19. Physico- chemical parameters of the formulated transdermal 
patches during the stability studies at room temperature (25°C)
Parameters F7 F8 F9 F13 F14
Physical appearance flexible, smooth and transparent
flexible, smooth 
and transparent
flexible, smooth 
and transparent
flexible, smooth 
and transparent
flexible, smooth 
and transparent
Weight variation (g) 0.354 + 0.02 0.349 + 0.04 0.309 + 0.03 0.356 + 0.01 0.351+ 0.02
Thickness (mm) 0.166 + 0.006 0.131+ 0.004 0.137 + 0.006 0.165 + 0.002 0.165 + 0.005
%moisture uptake 25.3 25.6 26.9 25 25.7
%moisture content 3.3 3.1 2.3 3.1 3.0
Folding endurance 245 256 277 243 241
%Drug content 99.8 100.1 100 99.6 100.4
%Flatness 100 100 99.9 100 99.9
% in vitro release 94.87 84.17 78.37 87.45 80.98
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Table: 20.  Cumulative percentage permeation studies from transdermal patches
at room temperature (25°C)
Formulation 
code
Cumulative 
Percentage 
Release Of 
Drug at
1h 2h 3h 4h 5h 6h 7h 8h
F7 9.76 + 0.02 20.58 + 0.01 30.13 + 0.04 31.42 + 0.01 42.46 + 0.07 51.86 + 0.09 71.55 + 0.07 74.74 + 0.03
F8 8.26+ 0.04 8.95+ 0.02 15.55+ 0.01 27.55+ 0.01 33.57 + 0.04 46.02 + 0.03 52.84 + 0.08 60.74 + 0.11
F9 10.67 + 0.05 20.74 + 0.04 35.77+ 0.04 42.15+ 0.03 54.04+ 0.03 56.98 + 0.02 67.34 + 0.02 70.10+ 0.03
F13 10.01+ 0.06 16.59 + 0.04 25.26+ 0.05 35.64 + 0.01 43.94 + 0.01 48.33 + 0.01 58.88 + 0.01 70.05 + 0.04
F14 8.11+ 0.02 12.62+ 0.01 27.79+ 0.03 36.34 + 0.04 38.73 + 0.03 46.14 + 0.01 58.28 + 0.01 63.51 + 0.02
F15 9.73+  0.01 11.45 + 0.07 14.29+ 0.04 18.85 + 0.02 19.90 +  0.06 28.14 + 0.02 42.40 + 0.04 48.71+ 0.04
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F16 825.88+ 0.01 28.44 + 0.07 33.34+ 0.04 36.87 + 0.02 45.44 +  0.06 56.73 + 0.02 62.96 + 0.04 77.64 + 0.04
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Table: 21. Evaluation studies of PLO gels at room temperature (25°C)
Formulation code pH Viscosity Drug content
F15 5.8 2932 99.8
F16 6.5 3204 100
Table: 22. Physico- chemical parameters of the formulated transdermal patches
during the stability studies at 40°C
Parameters F7 F8 F9 F13 F14
Physical appearance flexible, smooth and transparent
flexible, smooth 
and transparent
flexible, smooth 
and transparent
flexible, smooth 
and transparent
flexible, smooth 
and transparent
Weight variation (g) 0.353 + 0.02 0.349 + 0.01 0.309 + 0.03 0.356 + 0.04 0.351 + 0.01
Thickness (mm) 0.166 + 0.003 0.131 + 0.004 0.137 + 0.007 0.165 + 0.005 0.165 + 0.007
% moisture uptake 25.3 25.6 26.9 25 25.0
% moisture content 3.2 3.0 2.2 3.0 3.0
Folding endurance 243 256 275 243 243
% Drug content 99.7 100 100 99.1 100
% Flatness 100 100 99.9 100 99.6
% in vitro release 93.22 82.10 78.37 86.92 80.07
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Formulation 
code
Cumulative 
Percentage 
Release Of 
Drug at
1h
F7 9.7 + 0.09
F8 7.95 + 0.08
F9 12.47 + 0.03
F13 9.93+ 0.09
F14 8.83+ 0.01
F15 9.9+ 0.01
F16 25.14+ 0.01
Table:23. Cumulative 
pH Viscosity Drug content
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percentage 
permeation studies 
from transdermal 
patches at 40°C
Table:24. Evaluation 
studies of PLO gels 
at 40°C
Formulation code
F15 5.7 2930 99.8
F16 6.3 3200 100
Figure: 23. COMPARATIVE CUMULATIVE PERCENTAGE PERMEATION OF GLYBURIDE FROM 
SELECTED FORMULATIONS DURING STABILITY STUDIES
SUMMARY AND CONCLUSION
An attempt to develop transdermal therapeutic system for  glyburide was carried out for the purpose of 
attaining maximum bioavailability by tress passing pre-systemic hepatic metabolism and other side effects. The 
matrix type patches were prepared using four polymers namely PVA, PVP, HPMC, EC (F1- F14) and the PLO 
gels (F15-F20) were prepared by mixing the oil and aqueous phase.
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The compatibility studies using TLC and IR spectral study revealed the absence of interaction between the 
drug and the polymers used.
The formulated transdermal patches (F1-F14) and PLO gels (F15-F20) were evaluated for the physico-
chemical parameters, in vitro permeation and stability studies.
Transdermal patches
All the formulated transdermal patches were transparent, smooth and flexible in appearance. The patches 
showed a significant variation in their average weight, which might be due to the variation in the proportions of 
polymers used. There was no significant change observed in the thickness of all the fourteen patches.
The moisture uptake and moisture content studies revealed that all the formulated transdermal patches were 
having the low moisture uptake and moisture content when compared with the formulations F5 and F6. Polymer 
PVP showed the highest % S.I and low % S.I for EC polymer.
All the patches showed uniform drug content. The higher value of folding endurance can be attributed to the 
higher proportion of hydrophilic polymers. The patches exhibited ~100% flatness indicating no constriction.
Among the formulations prepared  F7,  F8,  F9,  showed a better  in  vitro  drug release  profile  across  the 
cellophane membrane. This might be attributed to the nature of polymer, plasticizer and permeation enhancer 
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used. Among the above mentioned formulations  (F7,  F8,  F9), the F7 formulation which showed better release of 
drug was again evaluated by changing the penetration enhancers (F13, F14). The permeation rates of glyburide 
were arranged in the following increasing order:  DMSO > Tween 80 > SLS.  Transdermal patches F7 was better  
when compared to F13  and F14. 
PLO gels
 All the PLO formulations F15- F20 showed drug content in the range of 98.6% – 100.8% indicating 
uniform distribution of drug throughout the base. The viscosity of all the formulations was found to be in the  
range 2752-3455 poise. The pH of all the formulations was around the skin pH and found to be in the range of  
5.81 to  6.65.  All  the  formulations  were  smooth  in  feel  and free  from grittiness  which increases  the  patient 
compliance. From the above studies it may be concluded that formulation F16, is an effective formulation for 
transdermal delivery, as it showed higher cumulative percent drug release and drug content.
Stability studies:
As far the above results were concerned formulations F7, F8, F9 ,F13, F14, F15, and F16 were selected and 
subjected for stability studies at room temperature (25°C) and at 40°C for a period of 30 days. The stability study 
results signified that the selected patches and gels possess adequate shelf life till 30 days.
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    Among the transdermal patches prepared formulation F7 containing HPMC and EC at 2:2 ratio with DMSO 
as penetration enhancer  and formulation F16,  PLO gel  with 3% lecithin showed better  combinations for  the 
controlled release of glyburide. These formulations could be predicted to have continuous supply of glyburide at a 
desirable rate to systemic circulation, which improved day-to-day glycemic control in diabetic subjects. However 
long term pharmacokinetic and pharmacodynamic studies should be undertaken to establish the usefulness of 
these formulations.
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